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Executive Summary 
 
Many chemicals have been shown to produce tumors in rats and mice, especially 
liver is the most common target organ affected. Momfluorothrin, a new pesticide 
developed by Sumitomo Chemical Co. Ltd., induced hepatocellular tumors in the rat 
two-year bioassay and which is a close structural analogue of pyrethroid insecticide 
metofluthrin. The metofluthrin also induced rat liver tumors and results from the mode 
of action (MOA) analysis showed constitutive androstane receptor (CAR)-mediated 
MOA. Therefore, the MOA for momfluorothrin-induced rat hepatocellular tumors is 
also predicted to be the CAR-mediated MOA as it is for metofluthrin. A series of MOA 
analysis was conducted based on the International Programme on Chemical Safety 
(IPCS) framework to evaluate the human cancer risks of momfluorothrin in the present 
research. 
The IPCS framework composed of the following three questions. Question 1 is to 
establish an animal MOA for momfluorothrin-induced rat liver tumors, question 2 is to 
demonstrate the qualitative differences in the key events between rats and humans, and 
question 3 is to demonstrate the quantitatively differences in either kinetic or dynamic 
factors between rats and humans. 
In chapter 1, to establish the animal MOA for rat hepatocellular tumors induced by 
momfluorothrin, a series of in vivo and in vitro MOA analysis were conducted using 
wild type (WT) and CAR knockout (KO) rats or RNA interference (RNAi) technique. 
As a result of MOA analyses, defined key events (i.e. CAR activation, hepatocellular 
proliferations) and associative events (hepatic cytochrome P450 (CYP) 2B induction, 
increased liver weights, hepatocellular hypertrophy) in the CAR-mediated MOA were 
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identified in WT rats with strong dose-dependency and temporal consistency. In further 
studies using CAR KO rats and RNAi technique, it was elucidated that hepatocellular 
proliferation and CYP2B activity induced by momfluorothrin were depend on CAR 
activation. Thus, a plausible MOA for momfluorothrin-induced rat liver tumor 
formation have been established as CAR activated MOA and the answer to question 1 in 
the IPCS framework is yes. 
In chapter 2, to evaluate of human relevancy for rat hepatocellular tumors induced 
by momfluorothrin, some in vitro and in vivo assays were conducted using human 
culture hepatocytes and chimeric mice with human hepatocytes. In rat and human 
hepatocyte studies with momfluorothrin, CYP2B gene expression was significantly 
increased in both hepatocytes but replicative DNA synthesis was only increased in rat 
and not in human hepatocytes. This conclusion is strongly supported by the chimeric 
mouse study, where no increase in replicative DNA synthesis in human hepatocytes was 
also observed. As examination of the available data demonstrates that the MOA for 
momfluorothrin-induced rat liver tumor formation is qualitatively not plausible for 
humans and the answer to question 2 is yes. In addition, no stimulation of replicative 
DNA synthesis by NaPB and metofluthrin was demonstrated in chimeric mice with 
human hepatocytes.  
In conclusion, these data suggested that CAR activators including momfluorothrin 
have no carcinogenic risk for humans. 
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Introduction 
 
   I. Cancer bioassay 
   The current standard for evaluation of possible carcinogenic activity of a chemical 
in humans is the two-year bioassay in rodents, usually rats and mice. These animal 
cancer bioassays have been used for more than a half century to determine whether 
pesticides, pharmaceuticals, consumer products, industrial chemicals, food additives 
and other products might cause cancer or other health problems in humans. Inherent in 
rodent-based assessments was the assumption that the observation of tumors in 
laboratory animals could be meaningfully extrapolated to identify potential human 
carcinogens (Cohen, 2010; Boobis et al., 2006). However, some of them have been 
identified rodents-specific tumors throughout mechanism studies have brought together 
a fuller biological understanding of how chemicals induce neoplasia in animal studies 
(Whysner, Ross, and Williams 1996; Holsapple et al., 2006; Meek et al., 2014; Elcombe 
et al., 2014; Corton et al., 2014). Therefore, it is necessary to evaluate and extrapolate 
appropriately the human cancer risks from positive results of rodent carcinogenicity 
study. 
 
   II. IPCS Framework for analyzing the relevance of a cancer MOA for human 
In the early 2000s, as an analytical tool to provide a means of evaluating 
systematically the data available on specific carcinogenic response to a chemical in a 
transparent manner, frameworks for analyzing the MOAs by which chemicals produce 
tumors in laboratory animals and the relevance of such tumor data for human risk 
assessment have been developed by the IPCS and by the International Life Sciences 
Institute (ILSI) (Boobis et al., 2006, 2008; Cohen et al., 2004; Meek et al., 2003; 
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Sonich-Mullin et al., 2001). An MOA has been defined as a “biologically plausible 
sequence of key and associative events leading to an observed effect supported by 
robust experimental observations and mechanistic data” (Boobis et al., 2006). In terms 
of the human relevance of an animal carcinogenic MOA, there are three questions to 
consider (Boobis et al., 2006) before reaching a conclusion (Fig. 1).  
 
Figure 1. IPCS general scheme illustrating the main steps in evaluating the human relevance of 
an animal MOA for tumor formation (Figure is modified from Boobis et al., 2006).  
 
The questions have been designed to enable an unequivocal answer yes or no, but 
recognizing the need for judgment regarding sufficiency of weight of evidence (WoE). 
Answers leading to the left side of the diagram indicate that the WoE is such that the 
MOA is not considered relevant to humans. In contrast, answers leading to the right side 
of the diagram indicate either that the WoE is such that the MOA is likely to be relevant 
to humans.  
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III. Rats cancer bioassay in Momfluorothrin 
   Many chemicals have been shown to produce tumors in rats and mice. Analysis of 
rodent bioassay data demonstrates that for both the rat and the mouse liver is the most 
common target organ affected (Huff et al., 1991; Gold et al., 2001). In our recent case, 
Epsilon-Momfluorothrin (CAS# 1065124-65-3; 2,3,5,6-Tetrafluoro-4- 
(methoxymethyl)benzyl(Z)-(1R,3R)-3-(2-cyanoprop-1-enyl)-2,2-dimethylcyclopropane
carboxylate, referred to as momfluorothrin in this report, Figure 2A) was also induced 
hepatocellular tumors in the rat carcinogenicity study. 
 
 
Figure 2. Chemical structures of momfluorothrin (A) and metofluthrin (B). 
 
Momfluorothrin was developed as a type I synthetic pyrethroid insecticide consisting of 
two main isomers (RTZ: RTE ratio is 9:1) for use to treat crawling insects in both indoor 
residential settings and outdoor commercial/residential/barn settings. A summary of the 
results of 2-year bioassay using male and female Wistar rats fed diet containing 
momfluorothrin at 0, 200, 500, 1500, and 3000 ppm are shown in Table 1. The 
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incidences of the total number of animals with hepatocellular adenomas and/or 
carcinomas were 2, 0, 4, 12, and 33% for males, and 0, 0, 2, 2, and 10% for females, 
respectively. The combined incidence of hepatocellular adenoma and carcinoma was 
significantly increased in male and female rats given 3000 ppm momfluorothrin, with a 
non statistically significant increase being observed in male rats given 1500 ppm. The 
incidences of hepatocellular adenoma, carcinoma, and combined in males given 1500 
and 3000 ppm were equivalent to or higher than the maximum incidence of the 
historical control data, and the combined incidence of female rats given 3000 ppm was 
within the historical control data, but incidence of carcinoma was equivalent to the 
maximum incidence of the historical control data. Overall, treatment with 
momfluorothrin in rats for 2 years produced hepatocellular tumours in males at 1500 
and 3000 ppm (73 and 154 mg/kg/day) and in females at 3000 ppm (182 mg/kg/day) 
(ECHA, 2014). 
This research report was summarized based on the published data from Okuda et al., 
2017a, 2017b, and Yamada et al., 2014.  
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Table 1. Summary of liver alterations in rats treated with momfluorothrin in the 2-year tumorigenicity study. 
 
Sex    Males  Females 
Dose levels of momfluorothrin (ppm)  0 200 500 1500 3000  0 200 500 1500 3000 
Organ weight              
 104 weeks Relative liver weights  1.00 1.04 1.08 1.22** 1.66**  1.00 0.99 1.05 1.20** 1.46** 
Light microscopy (incidence)             
 104 weeks Hepatocellular hypertrophy 1/51 1/51 0/51 5/51 14/51**  0/51 0/51 0/51 3/51 10/51** 
Preneoplastic or neoplastic findings (incidence and %)              
 104 weeks Eosinophilic cell foci  0/51   
(0%) 
2/51   
(4%) 
3/51   
(6%) 
3/51   
(6%) 
20/51** 
(39%) 
 2/51   
(4%) 
0/51   
(0%) 
2/51   
(4%) 
5/51   
(10%) 
9/51* 
(18%) 
  Hepatocellular adenomas  1/51   
(2%) 
0/51   
(0%) 
2/51   
(4%) 
4/51   
(8%) 
8/51*     
(16%) 
 0/51   
(0%) 
0/51   
(0%) 
1/51   
(2%) 
1/51   
(2%) 
4/51   
(8%) 
  Hepatocellular carcinomas  0/51   
(0%) 
0/51   
(0%) 
0/51   
(0%) 
4/51   
(8%) 
9/51**   
(18%) 
 0/51   
(0%) 
0/51   
(0%) 
0/51   
(0%) 
0/51   
(0%) 
1/51   
(2%) 
  Combined hepatocellular 
adenomas/carcinomas 
1/51   
(2%) 
0/51   
(0%) 
2/51   
(4%) 
6/51   
(12%) 
17/51** 
(33%) 
 0/51   
(0%) 
0/51   
(0%) 
1/51   
(2%) 
1/51   
(2%) 
5/51* 
(10%) 
Historical control data 
a
   Average Range (min - max)  Average Range (min - max) 
  Eosinophilic cell foci  6.55% 0.0 - 44.0%  7.42% 0.0 - 56.0% 
  Hepatocellular adenomas  2.54% 0.0 - 8.0%  2.80% 0.0 - 10.2% 
  Hepatocellular carcinomas  0.47% 0.0 - 2.8%  0.32% 0.0 - 2.0% 
  Combined hepatocellular adenomas/carcinomas 3.01% 0.0 - 10.0%  3.12% 0.0 - 12.0% 
Note. Data are unpublished but refereed to ECHA (2014). For histopathology, data represent the number of animals with the lesion/total number of animals examined and incidence is shown in parentheses.  
Values of relative liver weight are presented as fold of the control at each dose level. 
Values significantly different from control (0 ppm) are: * p < 0.05, ** p < 0.01. Values within shaded areas indicate toxicologically significant change.  
a: Historical control data on liver tumors on 104-weeks studies in RccHanTM:WIST, Wistar Hannover rats compiled from 104 weeks bioassays performed at Harlan Laboratories Ltd. Itingen/Switzerland. 
Table is adapted from Okuda et al., (2017a). 
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Chapter 1 
 
MOA analysis for rat hepatocellular tumors produced by the synthetic pyrethroid 
momfluorothrin: evidence for CAR activation and mitogenicity in male and female 
rats 
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Introduction 
 
   Postulated MOA for rodent liver tumors formation by momfluorothrin 
  According to the Cohen (2010), there are two ways that a chemical can alter the 
incidence of cancer: (1) by damaging DNA directly or (2) indirectly by increasing the 
number of DNA replications resulting in an increase in the spontaneous errors in DNA. 
Several MOAs which have been identified for liver carcinogenesis both in humans and 
in rodent models are shown in Table 2. MOAs that have evidence of human relevance 
are highlighted in bold letters (e.g. DNA-reactive carcinogens (genotoxic compound), 
estrogen receptor activation, increased cytotoxicity, infections, and metal overload). 
While, there are a number of MOAs with no relevance to humans, including peroxisome 
proliferation, enzyme induction, statine-mediated alterations in liver metabolism, and 
increased apoptosis (Cohen, 2010; Cohen and Arnold, 2011). 
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Momfluorothrin is clearly not genotoxic, being negative in a variety of in vivo and 
in vitro genotoxicity assays (Ames test, in vitro chromosomal aberration test, in vitro 
gene mutation assay, unscheduled DNA synthesis (UDS) assay and mouse micronucleus 
test) (ECHA, 2014). Moreover, momfluorothrin is a close structural analogue of the 
type I pyrethroid insecticide metofluthrin (Fig. 2B) and high doses of metofluthrin have 
also been shown to produce hepatocellular tumors in rats (Deguchi et al., 2009). Results 
in in vivo and in vitro MOA studies, metofluthrin induced hepatic CYP2B subfamily 
enzymes as a surrogate marker of CAR and hepatocellular replicative DNA synthesis in 
rats (Deguchi et al., 2009; Hirose et al., 2009; Kushida et al., 2016; Yamada et al., 2009, 
2015). From a read-across approach, the MOA for rat hepatocellular tumors induced by 
momfluorothrin was postulated the same as that of metofluthrin, that is CAR-mediated 
MOA. This MOA is similar to that of certain other non-genotoxic agents which are 
CAR activators, such as phenobarbital (PB) (Carmichael et al., 2011; Holsapple et al., 
2006; Osimitz and Lake, 2009) which can produce liver tumors in rats and mice (IARC, 
2001; Whysner et al., 1996).  
 
Key and associative events in the CAR-activated MOA 
In CAR-activated MOA, many key events (i.e. an empirically observable causally 
precursor step to the adverse outcome that is itself a necessary element of the MOA) 
and associative events (i.e. biological processes that are themselves not causal necessary 
key events for the MOA, but are reliable indicators or markers for key events) have 
been identified (Elcombe et al., 2014). Key events are required events for the MOA, but 
often are not sufficient to induce the adverse outcome in the absence of other key events. 
Associative events can often be used as surrogate markers for a key event in a MOA 
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evaluation or as indicators of exposure to a xenobiotic that has stimulated the molecular 
initiating event or a key event.  
In a recent evaluation of the MOA for PB-induced rodent liver tumor formation, key 
events in the MOA were considered to be CAR activation, altered gene expression 
specific to CAR activation, increased cell proliferation, and the development of altered 
hepatic foci leading to liver tumor formation; whereas associative events included the 
induction of CYP enzymes (in particular the CYP2B subfamily enzymes), liver 
hypertrophy (increased liver weight and hepatocellular hypertrophy) and inhibition of 
apoptosis (Elcombe et al., 2014). If a key event (or events) is an essential element for 
carcinogenesis, it must precede the appearance of the tumors (Cohen and Arnold, 2016). 
A scheme of key and associative events in the postulated MOA for 
momfluorothrin-induced rat hepatocellular tumor formation is shown in Figure 3. To 
determine whether this postulated MOA (CAR activated MOA) is correct, in vivo and in 
vitro experiments were conducted following the IPCS framework against the modified 
Bradford Hill considerations (Meek et al., 2014; Sonich-Mullin et al., 2001) which are: 
1. Postulated MOA. 
2. Key events; associated critical parameters. 
3. Dose-response relationships. 
4. Temporal association. 
5. Strength, consistency, and specificity of association of key events and tumor 
response. 
6. Biological plausibility and coherence. 
7. Possible alteration MOAs. 
8. Uncertainties, Inconsistencies, and data gaps. 
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9. Conclusion about the MOA. 
These obtained experimental and analytical data have already been published from 
Toxicological Sciences (Okuda et al., 2017a). 
 
 
Figure 3. Schematic representation of key and associative events in the proposed MOA for 
momfluorothrin-induced rat hepatocellular tumor formation. The MOA for 
momfluorothrin-induced rat liver tumor formation is postulated to involve activation of the CAR, 
which results in a pleiotropic response including the stimulation of CYP2B subfamily enzymes, 
hepatocellular hypertrophy and increased hepatocellular proliferation. Although hepatocyte labeling 
index values, determined as 5-bromo-2´-deoxy-uridine (BrdU) labeling index, may return toward 
control levels with continued momfluorothrin treatment, the number of cell replications in treated 
animals will be enhanced due to the increased total number of hepatocytes per animal. The continued 
stimulation of cell proliferation may lead to tumor formation as a result of critical errors being 
produced during cell replication and/or to the enhanced proliferation of spontaneously initiated 
pre-neoplastic hepatocytes (Cohen and Arnold, 2011; Schulte-Hermann et al., 1983). Prolonged 
treatment results in the formation of altered hepatic foci and liver tumors. Figure is adapted from 
Okuda et al., (2017a). 
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Materials and Methods 
 
Chemicals 
Test chemicals were obtained from the following manufacturers: momfluorothrin 
(Lot no. 9CM0109G; purity 95.7%; storage condition, cold storage) and 
epsilon-metofluthrin (Lot no.100702; purity 98.8%; storage condition, cold storage; 
referred to as metofluthrin in this article) were provided by Sumitomo Chemical Co., 
Ltd. (Tokyo, Japan); phenobarbital-Na (NaPB; Lot no.AWJ4960; purity 98.0%; storage 
condition, room temperature) was purchased from Wako Pure Chemical Industries, Ltd. 
(Osaka, Japan). 
 
Animals and husbandry 
All experiments were performed in accordance with The Guide for Animal Care 
and Use of Sumitomo Chemical Co., Ltd. 
HarlanRccHanTM:WIST (Wistar strain) rats aged 9 weeks were purchased from 
Japan Laboratory Animals, Inc., Hanno Breeding Center (Saitama, Japan) as this was 
the strain of rats used in the 2-year cancer bioassay. In addition, CAR KO rats with a 
Crl:CD (SD) genetic background aged 10 weeks and wild-type Crl:CD (SD) rats (WT) 
aged 11 weeks were purchased from SAGE labs, Inc. (Boyertown, Pennsylvania, 19512, 
USA) and Charles River Japan, Inc., Hino Breeding Center (Shiga, Japan), respectively. 
SD genetic background CAR KO rats were used as Wistar background KO rats were not 
available. Similar responses to momfluorothrin in the liver of wild type rats of both 
strains were observed in the present study (described later). Prior to the MOA analysis, 
BrlHan:WIST@Jcl(GALAS) (Wistar strain) rats aged 4 weeks were purchased from 
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CLEA Japan, Inc., Fuji Breeding Center (Shizuoka, Japan) and used in the toxicity 
screening study at the early stage of development of this chemical; liver samples from 
the BrlHan:WIST@Jcl(GALAS) rats were subjected to the global gene expression 
profile analysis and the data are presented in this paper.  
Animals were acclimatized to laboratory conditions for 7 days prior to treatment in 
the in vivo assay. During the course of the study, the environmental conditions in the 
animal room were set to maintain a temperature range of 22-26°C and a relative 
humidity range of 40 - 70, with frequent ventilation (more than 10 times per hour) and 
a 12 hour light (8:00 - 20:00)/ 12 hour dark (20:00 - 8:00) illumination cycle. A 
commercially available pulverized diet (CRF-1; Oriental Yeast Co., Ltd, Tokyo) and 
filtered tap water were provided ad libitum throughout the study. The animals were not 
fasted overnight prior to sacrifice in the present MOA studies, but they were fasted in 
the toxicity screening study. 
 
Design for in vivo studies using Wistar rats 
In the present MOA study, three different experiments were conducted for 
evaluating time-course, dose-dependency and reversibility. Male and female rats (ten 
animals/dose/sex) fed diets containing momfluorothrin at 0 (control) and 3000 ppm (the 
highest dose in the 2-year bioassay, a tumor inducing dose level) for 7 and 14 days to 
evaluate the time-course of changes. For evaluation of the dose-dependency, 
momfluorothrin was administered at 0, 200, 500, 1500, and 3000 ppm to both sexes (ten 
animals/dose/sex) for 7 days; these levels were consistent with those of the 2-year 
bioassay. Furthermore, the reversibility of hepatic effects was evaluated in male rats (ten 
animals/dose) by cessation of treatment for 7 days after 7-days treatment with 
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momfluorothrin at 0 and 3000 ppm. 
 
Design for in vivo studies using CAR KO rats 
Male Crl:CD (SD) (WT) and CAR KO rats (five animals/group, respectively) were 
fed diets containing momfluorothrin at 0 or 3000 ppm for 7 days to clarify whether the 
hepatocellular proliferation involved CAR activation. As shown below, since 
momfluorothrin treatment at 3000 ppm for 7 days significantly increased CYP2B 
activity, liver weight and replicative DNA synthesis in male Wistar rats, the same 
treatment time was selected for this experiment. This model has been quite recently 
developed and only limited data have been published (Chamberlain et al., 2014). Thus, 
two additional CAR-mediated MOA liver tumor inducers NaPB (1000 ppm) (Rossi et 
al., 1977) and metofluthrin (1800 ppm) (Yamada et al., 2009) were examined in the 
present study to confirm reliability of the CAR KO rat model. Administration of PB in 
drinking water (500 ppm, the corresponding daily intake was of 39.5 mg/kg/day in 
males and of 46.7 mg/kg/day in females) caused liver adenomas in male and female 
Wistar rats (Rossi et al., 1977). In this study, treatment of 1000 ppm NaPB in diet 
revealed a similar range of daily intake (approximately 50 mg/kg/day, see Table 5).  
Although we consider that eight to ten rats per group is preferred for reliable 
evaluation of BrdU labeling under the study conditions we used, due to limitation of the 
number of the CAR KO rat availability, five animals per group were used in the present 
study. Since small numbers of animals were used (5 rats/group), to observe any 
expected CAR-mediated alterations (even a tendency) in the WT animals, two sets of 
experiments (5 rats/group in each experiment) were conducted in the WT rats. 
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Observations and tissue sampling 
Mortality, body weights, and food consumption were monitored throughout the 
studies. For evaluation of replicative DNA synthesis, Alzet minipumps (Model 2ML1; 
Alzet Corporation, Palo Alto, CA, USA) containing BrdU (a structural analog of 
thymidine that incorporates into nuclear DNA and is used as a surrogate marker of cell 
proliferation (Wood et al., 2015), Sigma Company, St Louis, MO, USA) with a release 
rate of 200 μg/hour, were implanted in the subcutaneous tissue of rats under isoflurane 
anesthesia on the day prior to 4 days of the scheduled euthanization to avoid the effects 
of a palatability problem at the early phase of the study. After 7- or 14-day treatment 
period, rats were sacrificed under deep anesthesia by isoflurane without prior fasting on 
the morning of day 8 or 15, and then livers were excised quickly and weighed. Some 
liver tissue was stored in RNA stabilization solution (Ambion, Austin, TX, USA) at 
-80°C until analyzed for gene expression. The remaining liver tissue was processed for 
hepatic CYP enzyme activity analysis, histopathology, and cell proliferation 
measurement. 
 
Liver histopathology  
Segments of livers from all surviving animals were fixed in buffered 4% 
paraformaldehyde or 10% neutral buffered formalin, embedded in paraffin, sectioned, 
stained with hematoxylin and eosin, and examined by light microscopy. In addition, the 
left lateral lobe in the control and treatment groups was prefixed by perfusing 2.5% 
glutaraldehyde in 0.2 M phosphate buffer (pH 7.4) using a syringe for 2 animals/group 
in Wistar rats. The sample blocks were post-fixed in 2% osmium tetroxide, dehydrated, 
and embedded in epoxy resin. Ultra-thin sections were prepared, stained with uranyl 
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acetate and lead citrate, and examined by JEM-1400 transmission electron microscopy 
(JEOL, Tokyo, Japan).  
 
Hepatocyte replicative DNA synthesis from BrdU-labeling indices  
Hepatocyte replicative DNA synthesis was determined in the livers from all 
surviving animals by an immunohistochemical method using BrdU monoclonal 
antibody (Deguchi et al., 2009; Yamada et al., 2014). BrdU labeling was analyzed 
microscopically in a blinded manner with more than 2000 hepatocytes per rat being 
evaluated. A small section of duodenum from each animal was also processed to serve 
as a control for confirming systemic availability of BrdU and immunohistochemical 
staining.  
 
Quantitative real-time polymerase chain reaction of the selected genes  
Using liver samples from male Wistar rats treated with momfluorothrin at 3000 
ppm for 7 and 14 days, hepatic CYP1A2, CYP2B1/2, CYP3A1, CYP3A2, and CYP4A1 
mRNA expression levels were analyzed by quantitative real-time PCR. Hepatic 
CYP2B1/2 and CAR mRNA levels were also analyzed in samples from the in vitro 
RNAi experiment using rat hepatocytes and in in vivo study of CAR KO rats, 
respectively. Total RNA from hepatocytes was extracted using Isogen solution (Nippon 
Gene) and RNeasy Mini Kit (Qiagen) with on-column DNase treatment to avoid 
genomic DNA contamination. Total RNA was quantified by UV analysis at 260 nm and 
280 nm using a UV spectrometer (NanoDrop 2000, Thermo Fisher Scientific). The total 
RNA solution was stored at -80 ºC until required for complementary DNA (cDNA) 
generation. cDNA was prepared from total RNA by reverse transcription using the High 
 20 / 120 
 
Capacity cDNA Reverse Transcription Kit for reverse transcription polymerase chain 
reaction (RT-PCR) (Applied Biosystems) according to the kit supplier's instructions. 
The reaction mixture (20 µL) containing 10x RT Buffer containing total RNA (10 – 100 
ng) (2 µL), 25x dNTP mix (0.8 µL), 10x RT Random Primers (2 µL), 20U/µL RNase 
Inhibitor (1 µL) and 50U/µL MultiScribe Reverse Transcriptase (1 µL) in diethyl 
pyrocarbonate-treated water was incubated at 25 ºC for 10 min, 37 ºC for 120 min and 
85 ºC for 5 min. The cDNA solution was stored at -80 ºC until required for real-time 
PCR assays. The primer and probe sets are shown in Table 3. 
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Table 3. Primer and prove set. 
 
 
  
Species 
Target 
mRNA 
Forward Primer Reverse Primer Probe 
Product 
size 
Rat CYP1A2 GAAGCCCAGAACCTGTGAACA CCGATGTCTCGGCCATCTT CAGGCCTGGCCACGCTTCTCC 70bp 
 
CYP2B1/2 GCTCAAGTACCCCCATGTCG ATCAGTGTATGGCATTTTACTGCGG Not used 109bp 
 
CYP3A1 AGTCGTCCTGGTGCTCCTCTAC CCCAGGAATCCCCTGTTTCT ATTTGGGACCCGCACACATGGACT 73bp 
 CYP3A2 AAACCACCAGCAGCACACTCT CAGGGCCCCATCGATCTC TCTTGTATTTCCTGGCCACTCACCCTGA 95bp 
 CYP4A1 TCCAGGTTTGCACCAGACTCT TCCTCGCTCCTCCTGAGAAG CCCGACACAGCCACTCATTCCTGC 67bp 
 
GAPDH GCTGCCTTCTCTTGTGACAAAGT CTCAGCCTTGACTGTGCCATT TGTTCCAGTATGATTCTACCCACGGCAAG 129bp 
      
Mouse Cyp2b10 CAGGTGATCGGCTCACACC TGACTGCATCTGAGTATGGCATT Not used 70bp 
 
GAPDH TGTGTCCGTCGTGGATCTGA CCTGCTTCACCACCTTCTTGA CCGCCTGGAGAAACCTGCCAAGTATG 77bp 
      Human CYP2B6 TTGTTCTACCAGACTTTTTCACTCATC GGAAAGTATTTCAAGAAGCCAGAGA TCTGTATTCGGCCAGCTGTTTGAGCTC 83bp 
 
GAPDH GACACCCACTCCTCCACCTTT CATACCAGGAAATGAGCTTGACAA CTGGCATTGCCCTCAACGACCA 79bp 
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Hepatic microsomal CYP enzyme activity 
Hepatic microsomal CYP enzyme activity was determined in selected liver samples 
such as from the dose-response study. A portion of liver (approximately 0.5 g) was 
homogenized in 4 volumes of 154 mM KCl containing 50 mM Tris/HCl buffer pH7.4 
using a Potter-type Teflon-glass homogenizer. Whole liver homogenates were 
centrifuged at 9,000 × g for 20 min at 4 °C to separate S9 fractions. The protein content 
of the S9 fractions was determined using the DC protein assay kit (Bio-Rad, CA) 
employing bovine serum albumin as standard (Bradford, 1976). CYP2B activity was 
determined as 7-pentoxyresorufin O-depentylase (PROD) activity by fluorometric 
analysis using the specific substrate for CYP2B enzyme. The reaction mixture (200 µL) 
consisted of 3 µM 7-pentoxyresorufin, 10 µM dicoumarol, 1 mM NADPH, 1 µL S9 
fraction in 100 mM Tris/HCl buffer pH7.4 in 96-well microplates. After incubation for 
10 min at 37 ºC, the reaction was stopped by addition of 100 µL acetonitrile. The 
fluorescence of the sample was measured with a microplate reader (Saffire II, Tecan) 
with an excitation wavelength of 550 nm and an emission wavelength of 589 nm. 
Enzyme activity was calculated from the fluorescence of a standard curve of the 
resorufin product.  
 
Evaluation for CAR involvement on the MOA for CYP2B1/2 mRNA induction in 
cultured rat hepatocytes using the RNAi technique 
The assay was basically conducted as previously described (Deguchi et al., 2009). 
On day 0, primary cultured hepatocytes were obtained from a single male rat per 
experiment (HarlanRccHanTM:WIST rats, at the age of 9 weeks) by a modified 
two-step collagenase digestion method. Rat liver was perfused and hepatocytes were 
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dispersed from digested liver and washed with William’s E medium (GIBCO) three 
times by centrifugation. The hepatocytes were cultured in supplemented 2 mL William’s 
E medium (5% fetal bovine serum [GIBCO], 100 U/ml penicillin [Nakaraitesque], 
100g/ml streptomycin [Nakaraitesque], 2 mM L-glutamine [Nakaraitesque], 0.1M 
insulin [Sigma-Aldrich], 1M dexamethasone [Sigma-Aldrich], 0.2mM ascorbic acid 
[Sigma-Aldrich], and 10 mM nicotinamide [Sigma-Aldrich] ) in a six-well plate coated 
with collagen I (AsahiTechnoGlass), at a density of approximately 4 x 10
5
 cells/well, 
and allowed to attach for 3 hours at 37 ºC in a humidified chamber. After 3 hours, the 
culture dishes were gently swirled and fresh medium was added after removing 
unattached hepatocytes. 
On day 1, cells were rinsed and supplemented with serum/antibiotics free medium 
(2 mL). siRNA (1 g) for CAR (sense strand: 
5’-GCUCACACACUUUGCAGAUAUCAAU-3’, antisense strand: 
5’-AUUGAUAUCUGCAAAGUGUGUGAGC-3’, Hayashi-Kasei Co., Ltd.) or negative 
control (NC; Stealth RNAi Negative Control with Medium GC, Code No.; 12935-300, 
Invitrogen), and 1 L of MATra-si Reagent (IBA) were each diluted with 200L of 
serum/antibiotics free medium according to the manufacturer’s instructions, and the two 
solutions were gently mixed. After 20 min, the transfection mixtures (200L) were 
added to the cells, and the culture plates were placed on a magnet plate (IBA) for 15 
min. After 4 hours, the medium was changed to the supplemented Williams E medium 
containing serum and antibiotics. 
Following the transfection (on day 1), hepatocytes were treated with 50 M of 
NaPB and 100 M of momfluorothrin in medium for 2 days. A concentration of 50 M 
of NaPB was selected as this concentration has previously been shown to induce 
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CYP2B-dependent enzyme activity in cultured rat hepatocytes (Deguchi et al., 2009; 
Hirose et al., 2009). Medium was changed on a daily basis thereafter. The control group 
was treated in the same manner without test chemical. The experiment was examined 
using three wells for each group. On day 3, hepatocytes were washed with 
phosphate-buffered saline (PBS) and the total RNA was extracted using Isogen (Nippon 
Gene, Japan). During the experiment, no cytotoxicity was observed visually and there 
was no change in expression levels of the housekeeping gene 
(glyceraldehyde-3-phosphate dehydrogenase, GAPDH). 
 
Global gene expression analysis  
Since detailed MOA for momfluorothrin-induced liver tumor production was 
evaluated for the key and associate evens in the current MOA studies, the additional 
data of global gene expression analysis in the general toxicity study of momfluorothrin 
may not be essential for prediction of the MOA for momfluorothrin-induced liver tumor 
production. However, in the general toxicity studies, animals are usually fasted prior to 
euthanization to avoid confounding by possible variation of food consumption. In 
contrast, since it is well known that fasting alters the cytochrome P450 profile affecting 
drug/chemical metabolism (Maronpot et al., 2010; Sohn and Fiala, 1995), the data of 
global gene expression analysis in the general toxicity study with fasting may provide 
valuable information for considering newly postulated MOA of other compounds at the 
point of departure of the MOA study. The analysis was determined in livers from male 
BrlHan:WIST@Jcl(GALAS) rats (4 animals per groups) treated with momfluorothrin at 
0 and 3000 ppm for 2 weeks; the animals were treated under the same conditions as in 
the MOA studies described above, excepting for fasting prior to euthanization. Details 
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of the analytical methods are shown in Supplementary materials. The gene expression 
data can be downloaded from the National Center for Biotechnology Information Gene 
Expression Omnibus (Accession No. GSE94738; 
http://www.ncbi.nlm.nih.gov/geo/info/linking.html.). The obtained gene expression data 
were subjected to hierarchical clustering analysis with GeneSpring GX 13.1 software 
(Agilent Technologies). Clustering was conducted with the probe sets, whose expression 
was known to be changed in our reference data; carbon tetrachloride (CCl4) and 
thioacetamide as cytotoxic compounds (Abe et al., 2014; Manibusan et al., 2007), 
clofibrate as a peroxisome proliferator-activated receptor alpha (PPARα) activator 
(Corton et al., 2014), and NaPB as a CAR activator (Elcombe et al., 2014) for 2 weeks.  
 
Statistical analysis 
For comparison among multiple groups, if the variables exhibited a normal 
distribution by the Bartlett-test, the Dunnett-test was applied for a comparison of the 
treated groups with the control group. The Steel-test was applied instead of the 
Dunnett-test when the data did not exhibit a normal distribution. For comparison 
between two groups, the F-test was applied to compare treated groups with the control 
group. If the variance was homogeneous, Student’s t-test was used. If the variance was 
heterogeneous, the Aspin-Welch-test was used. Two-tailed tests were employed for 
evaluation except for BrdU labeling index and BrdU labeling index was evaluated by 
one-tail test with p≤0.05 and 0.01 as the levels of significance. 
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Results 
 
Analysis for selected hepatic CYP mRNA levels 
In the MOA studies, the effect of momfluorothrin on some selected CYP mRNA 
levels were determined in the livers of male Wistar rats treated with momfluorothrin at 
3000 ppm for 7- and 14 days (Fig. 4). While hepatic CYP2B1/2 mRNA levels were 
significantly increased after 7 and 14-day treatment (18- and 16-fold, respectively), 
CYP3A1 and CYP4A1 mRNA levels were only marginally increased after 7- or 14-day 
treatment (less than 1.5-fold). No significant changes were observed in CYP1A2 and 
CYP3A2 mRNA levels. These findings suggested that momfluorothrin activates CAR 
but not either Aryl hydrocarbon receptor (AhR) or PPARα. 
 
 
Figure 4. Selected hepatic CYP mRNA expression levels in Wistar male rats treated with 
momfluorothrin. Male Wistar rats were treated with momfluorothrin at 0 (control) and 3000 ppm for 7 
and 14 days and selected hepatic CYP mRNA expression levels were examined by RT-PCR. Data are 
presented as fold increase to control as mean ± SD (N=6). Values statistically different from control are: 
*p<0.05; ** p<0.01. Figure is adapted from Okuda et al., (2017a). 
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Evaluation of CAR involvement in CYP2B induction in cultured rat hepatocytes 
using the RNAi technique  
To confirm whether hepatic CYP2B induction (i.e. CYP2B1/2 mRNA) by 
momfluorothrin involves CAR activation, the effect of CAR knockdown by the RNAi 
technique on CYP2B induction by momfluorothrin was investigated in a rat cultured 
hepatocyte system. A concentration range finding experiment with 5 - 1000 M 
momfluorothrin demonstrated that CYP2B1/2 mRNA was significantly increased at 100 
M and higher concentrations with the peak effect being observed at 100 M (2.6-fold 
of control) (Fig. 5A). Subsequent experiments were performed with 100 M 
momfluorothrin.  
When rat hepatocytes were treated with CAR-siRNA together with either 50 M 
NaPB or 100 M momfluorothrin, CAR mRNA levels were significantly suppressed by 
80% and 81% of each negative CAR-siRNA control (NC) in NaPB and momfluorothrin 
treated groups, respectively (Fig. 5B and 5C). Under the CAR-suppressed condition, 
CYP2B1/2 mRNA levels in NaPB and momfluorothrin-treated groups were also 
reduced, respectively, by 67% (close to statistical significance, p=0.070) and 68% (close 
to statistical significance, p=0.067) compared with each NC (Fig. 5D and 5E). In 
addition, the data from CAR KO mice (Yamamoto et al., 2004) and rat cultured 
hepatocytes with CAR siRNA (Deguchi et al., 2009) demonstrated that CAR activation 
is necessary to induce CYP2B mRNA by NaPB. Therefore, these findings demonstrate 
that momfluorothrin is also a CAR activator bacause CYP2B1/2 mRNA was induced 
CAR dependently as well as NaPB. 
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Figure 5. Relative CAR (B, C) and CYP2B1/2 (D, E) mRNA expression levels in cultured 
hepatocytes treated with 50 μM NaPB (B, D) and 100 μM momfluorothrin (C, E). The 
concentration of momfluorothrin was determined based on the range finding study (A) and 100 µM 
momfluorothrin selected for the siRNA studies (B to E). NC means control siRNA as a negative 
control. NaPB + NC (B, D) and momfluorothrin + NC (C, E) are shown as percentage of control 
siRNA (NC) values. Data are presented as mean values±SD (N=3). For part A, values significantly 
different from control are: *p<0.05; **p<0.01. For parts B-E, values significantly different between 
untreated and NC treated hepatocytes are *p<0.05 and between NC and either 50 M NaPB or 100 
M momfluorothrin are ##p <0.01. Figure is adapted from Okuda et al., (2017a). 
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In vivo momfluorothrin time-course study in Wistar rats 
To investigate the time course of momfluorothrin-induced hepatic effects, male and 
female rats were treated with 0 (control) and 3000 ppm momfluorothrin for 7 and 14 
days. The data from this in vivo study are summarized in Table 4. There were no severe 
toxicities such as death or marked suppression of body weight and food consumption up 
to 14 days. As shown in Fig. 6A, relative liver weights were significantly increased to a 
similar extent in both sexes after 7 and 14 days treatment. While replicative DNA 
synthesis was also significantly increased after 7- and 14-days treatment in both sexes, 
the increase in replicative DNA synthesis was less marked after 14 days than after 7 
days in both sexes (Fig. 6B).  
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Table 4. Summary of liver alterations in rats treated with momfluorothrin in the MOA studies. 
Sex    Males  Females 
Momfluorothrin dose (ppm)  0 200 500 1500 3000  0 200 500 1500 3000 
Time-cause 
study 
7 days treatment Absolute liver weights  1.00 ND ND ND 1.12**  1.00 1.08 1.05 1.07 1.11* 
Relative liver weights  1.00 ND ND ND 1.17**  1.00 1.09* 1.04 1.10** 1.16** 
Replicative DNA synthesis  1.00 ND ND ND 5.30**  1.00 1.15 1.17 1.69* 2.79** 
CYP1A2 mRNA  1.00 ND ND ND 0.72  ND ND ND ND ND 
CYP2B1/2 mRNA  1.00 ND ND ND 17.78**  ND ND ND ND ND 
CYP3A1 mRNA  1.00 ND ND ND 1.37*  ND ND ND ND ND 
CYP3A2 mRNA  1.00 ND ND ND 0.93  ND ND ND ND ND 
CYP4A1 mRNA  1.00 ND ND ND 1.17  ND ND ND ND ND 
PROD activity  ND ND ND ND ND  1.00 0.88 1.00 1.88* 6.18* 
Hepatocellular hypertrophy 0/10   ND ND ND 4/10*   0/10   0/10   0/10   0/10   3/10  
Proliferation of SER 0/2 ND ND ND 0/2  ND ND ND ND ND 
14 days treatment Absolute liver weights  1.00 ND ND ND 1.24**  1.00 ND ND ND 1.05 
Relative liver weights  1.00 ND ND ND 1.26**  1.00 ND ND ND 1.12* 
Replicative DNA synthesis  1.00 ND ND ND 1.90*  1.00 ND ND ND 1.65* 
CYP1A2 mRNA  1.00 ND ND ND 0.79  ND ND ND ND ND 
CYP2B1/2 mRNA  1.00 ND ND ND 16.44**  ND ND ND ND ND 
CYP3A1 mRNA  1.00 ND ND ND 1.28  ND ND ND ND ND 
CYP3A2 mRNA  1.00 ND ND ND 0.97  ND ND ND ND ND 
CYP4A1 mRNA  1.00 ND ND ND 1.30*  ND ND ND ND ND 
PROD activity  ND ND ND ND ND  1.00 ND ND ND 6.88* 
Hepatocellular hypertrophy 0/10   ND ND ND 8/10**   0/10   ND ND ND 0/10  
Proliferation of SER 0/2 ND ND ND 0/2  ND ND ND ND ND 
Dose-depen
dency study 
7 days treatment  Absolute liver weights  1.00 1.01 1.05 1.08 1.09*  1.00 1.08 1.05 1.07 1.11* 
Relative liver weights  1.00 1.01 1.05 1.10** 1.14**  1.00 1.09* 1.04 1.10** 1.16** 
 Replicative DNA synthesis  1.00 1.13 1.17 1.77* 2.47**  1.00 1.15 1.17 1.69* 2.79** 
 PROD activity  1.00 0.60 0.80 1.20 2.80**  1.00 0.88 1.00 1.88* 6.18* 
  Hepatocellular hypertrophy 0/10   0/10   0/10   0/10   2/10   0/10   0/10   0/10   0/10   3/10  
Recovery 
study 
7 days treatment 
+7 days recovery 
Absolute liver weights  1.00 ND ND ND 1.04  ND ND ND ND ND 
Relative liver weights  1.00 ND ND ND 1.05  ND ND ND ND ND 
PROD activity 1.00 ND ND ND 1.28  ND ND ND ND ND 
Hepatocellular hypertrophy 0/10   ND ND ND 0/10   ND ND ND ND ND 
Note. Values excluding histopathological findings are presented as fold of the control at each dose level. For hepatocellular hypertrophy, data represent the number of animals with the lesion/total number of animals examined. Values significantly 
different from control (0 ppm) are: * p < 0.05, ** p < 0.01. Values within shaded areas indicate toxicologically significant change. For female, combined time-cause and dose-dependency studies was conducted. Thus, the female data of the 7-day 
treatment in the time-course study are adopted from those of the dose-dependency study. So, data of the control and 3000 ppm groups were repeatedly presented. PROD: 7-pentoxyresorufin O-depentylase,
 
SER: smooth endoplasmic reticulum, ND; not 
determined. Table is adapted from Okuda et al., (2017a). 
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Figure 6. Time-course effects on liver of Wistar rats treated with momfluorothrin. Relative liver 
weights (A) and hepatocyte replicative DNA synthesis (B) were determined in livers of male and 
female Wistar rats (N=10/group) treated with 0 (control) and 3000 ppm momfluorothrin for 7 or 14 
days. Data are presented as mean values±SD. Values statistically significant from control are: *p < 
0.05; **p < 0.01. Figure is adapted from Okuda et al., (2017a). 
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In vivo momfluorothrin dose-dependency and reversibility study in Wistar rats 
Male and female Wistar rats were treated with 0 (control), 200, 500, 1500 and 3000 
ppm momfluorothrin for 7 days. The selected data are presented in Table 4. Significant 
decreased body weight gains were observed at 1500 and 3000 ppm on day 3 due to 
palatability problems, however, these recovered to control levels by the end of the 
treatment period.  
At the two highest momfluorothrin dose levels (1500 and 3000 ppm), relative liver 
weight (Fig. 7A) and replicative DNA synthesis (Fig. 7B) were significantly increased 
in both male and female rats. A small non dose-dependent increase in relative liver 
weight was also observed in female rats given 200 ppm momfluorothrin (Fig. 7A). 
PROD activity was also statistically significantly increased in both sexes at 1500 and 
3000 ppm (except for males at 1500 ppm) (Fig. 7C). Increased PROD activity in males 
at 1500 ppm was a marginal change without statistical significance (1.2-fold of control). 
At 3000 ppm in both sexes, hepatocellular hypertrophy was observed in 2 and 3 of 10 
animals in males and females, respectively (Table 4). In contrast, male and female rats 
administered 200 and 500 ppm revealed no treatment related changes in hepatocyte 
replicative DNA synthesis, hepatocellular hypertrophy and PROD activity. 
All of the effects on liver weight, hepatocellular hypertrophy and PROD activity 
observed after 7 days of treatment with momfluorothrin returned to control levels upon 
cessation of treatment for 7 days (Table 4). The reversibility of the effect of 
momfluorothrin on hepatocyte replicative the DNA synthesis was not examined.  
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Figure 7. Dose-dependency of alterations in the Wistar rat liver treated with momfluorothrin. 
Relative liver weights (A), hepatocyte replicative DNA synthesis determined as BrdU labeling index 
(B), and hepatic PROD activity (C) were evaluated using male and female Wistar rat livers treated 
with momfluorothrin at 0, 200, 500, 1500, and 3000 ppm for 7 days. Data are presented as the mean 
values±SD; 10 animals/dose/sex for A and B, 6 animals/dose/sex for C. Values statistically 
significant from control are: *p < 0.05; **p < 0.01. 
Figure is adapted from Okuda et al., (2017a). 
  
(A) 
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In vivo momfluorothrin study in WT and CAR KO rats 
The hepatic effects of momfluorothrin were investigated in an in vivo study using a 
CAR KO rat model, which has only recently become commercially available. Male WT 
and CAR KO rats were given 0 (control) and 3000 ppm momfluorothrin for 7 days. In 
addition, the effects of 1800 ppm metofluthrin and 1000 ppm NaPB at, two known 
CAR-mediated MOA liver tumor inducers, were also investigated. The data are 
presented in Table 5. In the first experiment with WT rats, two of five animals treated 
with momfluorothrin showed severe toxicity due to a palatability problem as evidenced 
by marked decrease of body weights accompanied by considerable suppression of food 
consumption. However, there was individual variation of sensitivity to this palatability 
problem; the other 3 rats showed no such severe toxicities. These toxicities of 
momfluorothrin were also observed in the second experiment with WT rats and CAR 
KO rats, but the toxicity was less than those in the first experiment with WT rats.  
Under such conditions, NaPB, metofluthrin (except in the first experiment, where a 
1.6-fold increase was observed) and momfluorothrin significantly increased CYP2B1/2 
mRNA levels in WT rats suggesting CAR functionally responded in WT rats; but not in 
CAR KO rats, indicating that this CAR KO rat model is reliable (Fig. 8A and 8B, Table 
5). Replicative DNA synthesis was evaluated with groups of 5 rats in two separate 
experiments in WT rats. NaPB significantly increased (8.1 fold control) or increased 
(8.4 fold control) replicative DNA synthesis in the first and second experiments with 
WT rats, respectively; whereas metofluthrin increased (3.9 fold control) or significantly 
increased (4.1 fold control) and momfluorothrin significantly increased (3.1 fold control 
after excluding 2 animals with bad health condition in the first experiment) or increased 
(8.7 fold control) in the first and second experiments with WT rats, respectively.  
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Table 5. Summary of findings of the 7-day treatment study in WT and CAR KO Sprague Dawley rats 
 
      WT rats CAR KO rats 
   1
st
 experiment 
(Animal No.1-5) 
2
nd
 experiment 
(Animal No.6-10) 
    
   Control NaPB  
1000 ppm 
Metofluthrin 
 1800 ppm 
Momfluorothrin 
 3000 ppm 
Control NaPB  
1000 ppm 
Metofluthrin 
 1800 ppm 
Momfluorothrin 
 3000 ppm 
Control NaPB  
1000 ppm 
Metofluthrin 
 1800 ppm 
Momfluorothrin 
 3000 ppm 
Number of animals tested  5 5 5 5 5 5 5 5 5 5 5 5 
Test Item Intake (mg/kg/day)  - 50.1 88.3 84.4 - 52.5 84.8 110.9 - 50.2 77.1 123.2 
Death of animals  0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 
Final Body Weight (g)  431.3±19.0 447.7±23.3 448.8±18.6 396.8±20.9* 451.0±18.3 442.7±10.5 432.8±18.8 418.8±24.8* 454.9±30.4 472.1±20.9 447.7±32.2 456.7±16.6 
Total Body Weight Gain (g)  21.4±14.9 25.3±10.9 25.7±8.2 -15.7±24.1* 27.9±7.8 32.8±10.3 23.6±9.1 0.3±13.4** 23.1±7.3 40.6±15.6 18.2±8.9 21.8±5.8 
Food Consumption at 
termination of treatment 
(g/animal/day) 
 129.1±14.4 a 153.8±5.3* 149.0±3.0 82.3±31.1 147.2±19.7 159.3±3.9 140.1±7.8 107.0±11.8** 148.5±6.6 160.7±13.9 139.8±20.3 135.2±11.8 
Liver Weight Absolute (g)  13.78±0.88 18.03±0.89** 17.10±1.00** 13.61±1.92 15.57±0.47 18.08±1.26** 15.76±0.84 14.39±1.72 16.12±0.82 17.36±1.51 16.86±1.80 17.24±1.19 
(fold control)  1.00 1.31 1.24 0.99 1.00 1.16 1.01 0.92 1.00 1.08 1.05 1.07 
Relative (g/body weight×100)  3.20±0.20 4.03±0.23** 3.82±0.31** 3.42±0.35 3.46±0.17 4.09±0.30** 3.64±0.19 3.43±0.28 3.55±0.14 3.68±0.24 3.76±0.16 3.77±0.17 
(fold control)  1.00 1.26 1.19 1.07 1.00 1.18 1.05 0.99 1.00 1.04 1.06 1.06 
CYP2B1/2 mRNA level  
(% of control average) 
 100±47 31341±15125** 156±36 5416±2616* 100±16 24273±6593** 192±62* 2483±1636* 100±35 112±14 115±12 99±10 
(fold control)  1.00 313.41 1.56 54.16 1.00 242.73 1.92 24.83 1.00 1.12 1.15 0.99 
Replicative DNA synthesis (%)  0.90±0.53 7.28±5.53* 3.50±3.57 1.74±1.56 b 0.50±0.33 4.20±5.82 2.06±1.47* 4.36±6.35 3.56±1.38 3.70±2.24 1.78±0.93* 5.34±3.71 
(fold control)  1.00 8.09 3.89 1.93 b 1.00 8.40 4.12 8.72 1.00 1.04 0.50 1.50 
Due to limitation in the availability of the CAR KO rats, only five animals per dose could be used. For evaluation of replicative DNA synthesis, we consider that the numbers of animals per dose is sufficient although more optimal numbers would be 
eight to ten rats per dose. Since small number of animals examined (N=5) may result in an increased coefficient of variation (CV) and decreases the statistical power of the assay a second, experiment using wild type rats was conducted.  
a: For the control group of the 1
st
 experiment, food consumption was calculated by excluding two of the five animals due to severe diet spillage. 
b: For the momfluorothrin group of the 1
st
 experiment, two of five animals had severe toxicity as evidenced by marked suppression of body weight with decreased food consumption. When data of these two toxic animals are excluded, replicative DNA 
synthesis is 2.77 ± 0.96 (N=3). This value is 3.1-fold of control and statistically significant (p<0.01) compared to control, and is presented in Figure 5C as the data of the 1
st
 experiment of wild-type rats.  
Significantly different from control (F-test/Student t, or Welch test) : * p<0.05, ** p<0.01. Table is adapted from Okuda et al., (2017a). 
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Table 5. Summary of findings of the 7-day treatment study in WT and CAR KO Sprague Dawley rats (continued) 
 
      WT rats CAR KO rats 
   1
st
 experiment 
(Animal No.1-5) 
2
nd
 experiment 
(Animal No.6-10) 
    
   Control NaPB  
1000 ppm 
Metofluthrin 
 1800 ppm 
Momfluorothrin 
 3000 ppm 
Control NaPB  
1000 ppm 
Metofluthrin 
 1800 ppm 
Momfluorothrin 
 3000 ppm 
Control NaPB  
1000 ppm 
Metofluthrin 
 1800 ppm 
Momfluorothrin 
 3000 ppm 
Number of animals tested  5 5 5 5 5 5 5 5 5 5 5 5 
Histopathology: Liver              
Hypertrophy, hepatocyte, 
centrilobular 
± 0/5 1/5 5/5 0/5 0/5 1/5 4/5 0/5 0/5 0/5 0/5 0/5 
 + 0/5 4/5 0/5 0/5 0/5 4/5 0/5 0/5 0/5 0/5 0/5 0/5 
Hypertrophy, hepatocyte, diffuse ± 0/5 0/5 0/5 4/5$ 0/5 0/5 0/5 3/5 0/5 0/5 0/5 0/5 
Increased vacuole, glycogen-like, 
hepatocyte, diffuse 
± 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 1/5 0/5 0/5 
Infiltration, mononuclear, focal ± 3/5 3/5 4/5 3/5 4/5 4/5 2/5 3/5 4/5 3/5 4/5 2/5 
Vacuolation, hepatocyte, focal ± 0/5 1/5 0/5 0/5 0/5 1/5 0/5 0/5 0/5 0/5 0/5 0/5 
Vacuolation, hepatocyte, 
centrilobular 
± 0/5 1/5 0/5 0/5 0/5 1/5 0/5 0/5 0/5 0/5 0/5 0/5 
Necrosis, hepatocyte, focal ± 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 1/5 
For histopathology, data represent the number of animals with the lesion/total number of animals examined. Grade of histopathology: ±, Slight; +, Mild; 2+, Moderate; 3+, Severe.  
Significantly different from control (Wilcoxon rank sum test): $ p<0.05, $$ p<0.01. Table is adapted from Okuda et al., (2017a). 
  
$$ $$ $$ $ 
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In contrast to the WT rats, these chemicals did not produce any significant increases 
in replicative DNA synthesis in the CAR KO rats (Fig. 8C, Table 5). Increased liver 
weights and/or hepatocellular hypertrophy were also observed in WT rats treated with 
NaPB, metofluthrin or momfluorothrin, while no such effects were observed in the CAR 
KO rats treated with these chemicals even at similar intakes of test agents between WT 
and CAR KO rats (Table 5). Taken together, these data demonstrate that the induction 
replicative DNA synthesis in rats treated with NaPB, metofluthrin and momfluorothrin 
is mediated through CAR. 
When responses to momfluorothrin between Wistar rats (Table 4) and SD rats (Table 
5, WT rats in the CAR KO rat study) were compared, both strains responded 
qualitatively similarly to momfluorothrin, as demonstrated by increases in CYP2B1/2 
mRNA levels and replicative DNA synthesis. Quantitatively, the increases in CYP2B1/2 
mRNA levels was greater in SD rats, with the increases being 40-fold (mean of 2 
experiments with 54-fold and 25-fold increases) and 18-fold in SD and Wistar rats, 
respectively. However, for replicative DNA synthesis the response was equivalent in 
both SD and Wistar rats, the increases being 5.3-fold (mean of 2 experiments with 
1.93-fold and 8.72-fold increases) and 5.3-fold, respectively. Overall, these findings 
demonstrate that SD rats are responsive to momfluorothrin and hence that SD CAR KO 
rats may be employed to evaluate the CAR-dependency of the hepatic effects of 
momfluorothrin. 
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Figure 8. Effect of 1000 ppm NaPB, 1800 ppm metofluthrin and 3000 ppm momfluorothrin on 
CYP2B1/2 mRNA expression levels (A and B) and replicative DNA synthesis (C) in WT and 
CAR KO rats. Data are presented as mean values±SD (5 animals/group) with two experiments 
being performed in WT rats. For the momfluorothrin group in the first experiment, two of five 
animals revealed severe toxicity as evidenced by severe suppression of body weight with decreased 
food consumption. When data of the two toxic animals are excluded, replicative DNA synthesis is 
2.77 ± 0.96 (N=3). This value is 3.1-fold of control and statistically significant (p < 0.01) compared 
to control, and thus that value is plotted in this figure. Values statistically significant from control 
are: *p < 0.05; **p < 0.01. Figure is adapted from Okuda et al., (2017a).  
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Hepatic global gene expression and CYP mRNA levels 
Since this analysis was conducted prior to the present MOA studies, as described in 
the Methods section, the study conditions were not completely the same as the present 
MOA studies. However, the data obtained is useful in helping establish the MOA for 
momfluorothrin-induced liver tumor formation. The global gene expression profile 
analysis were conducted in the liver of male Wistar rats treated with momfluorothrin at 
3000 ppm for 14 days. Numbers of probe sets with 1.5-fold alterations compared to 
control group were 107 as up-regulation and 268 as down-regulation. Of these, some 
overlapped with genes altered after 14-day treatment with a CAR activator NaPB (1000 
ppm): up-regulated gene were Akr7a3, Aldh1a1, Aldh1a4, App, Atpif1, Ces2, Cd14, 
Cyp2b2/Cyp2b15, Ephx1, Ddc, Gsta2, Gstm1, RGD1562732_predicted, Snx10, 
Udpgtr2 and Zdhhc2; down-regulated genes were Atf5, Eif4g2, C4bpb, Ciapin1, 
LOC678772, Nrd1, Oat, Spetex-2G, Srebf1 and Zdhhc23. The result of hierarchical 
clustering analysis showed that the gene expression pattern of the liver from rats treated 
with momfluorothrin at 3000 ppm was clustered most closely to that of NaPB (Fig. 9).  
  
 40 / 120 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Hierarchical clustering analysis in Wistar male rats treated with momfluorothrin. 
Data are shown for clofibrate at 2500 ppm (a) and at 300 mg/kg bw/day (b), carbon tetrachloride at 
100 mg/kg bw/day (c), thioacetamide at 200 ppm (d) and 15 mg/kg bw/day (e), momfluorothrin at 
3000 ppm (f), and NaPB at 1000 ppm (g - k) and at 100 mg/kg bw/day (l). Wistar (a, d, f, g, i, and j), 
Crj:CD (SD) (b, c, e, and l), or F344 (h and k) male rats (3 or 4 animals/dose) were treated with test 
substances for 14 days. 
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Discussions 
 
In two-year carcinogenicity study, the incidence of hepatocellular tumors was 
increased in both male and female rats treated with higher dose of momfluorothrin. To 
assess the human relevance of these rat liver tumors, a series of mechanism study was 
conducted by using WT and KO rats or RNAi technique to elucidate the MOA for rat 
hepatocellular tumors induced by momfluorothrin and discussed with nine of the 
modified Bradford Hill considerations as below. 
 
1. Postulated MOA for momfluorothrin-induced rat liver tumor formation  
Metofluthrin, a close structural analogue to momfluorothrin, also increased 
hepatocellular tumors in rats. The MOA for tumor formation by metofluthrin in rats was 
shown to be similar to that of the prototypic CAR activator phenobarbital (Kushida et 
al., 2016; Yamada et al., 2009, 2015). This MOA involves activation of CAR, which 
results in a pleiotropic response including the stimulation of altered gene expression 
specific to CAR activation, hepatocellular hypertrophy and increased hepatocellular 
proliferation. Prolonged treatment results in the formation of altered hepatic foci and 
liver tumors. Activation of CAR, increased cell proliferation and the development of 
altered hepatic foci are considered to be key events in the MOA for tumor formation by 
such compounds as they constitute necessary steps in the MOA (Elcombe et al., 2014). 
The induction of CYP2B enzymes and liver hypertrophy (both morphological changes 
and increases in liver weight) are considered as associative events and as such represent 
reliable markers of CAR activation (Elcombe et al., 2014). Based on a close structural 
analogue, metofluthrin, the MOA for momfluorothrin-induced rat liver tumor formation 
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was postulated to also involve activation of CAR. The MOA data was summarized in 
Table 4 and 5 and the validity of this hypothesis was discussed below.  
 
2. MOA data 
Activation of the nuclear CAR (Key event #1) 
CYP2B enzyme induction in rodent liver involves activation of CAR (Deguchi et 
al., 2009; Wei et al., 2000; Yamamoto et al., 2004). To probe the role of CAR in the 
MOA for momfluorothrin-induced rat liver tumor formation, the RNAi technique was 
employed. CAR-siRNA was used to reduce CAR mRNA levels in order to examine 
CAR involvement on the effect of momfluorothrin on CYP2B1/2 mRNA induction in 
Wistar rat hepatocytes, employing a similar experimental design to that previously used 
in the metofluthrin study (Deguchi et al., 2009). NaPB was employed as a positive 
control for these studies. The treatment of Wistar rat hepatocytes with CAR-siRNA 
significantly reduced CAR mRNA in the presence of either NaPB and momfluorothrin, 
resulting in a reduction in the magnitude of induction of CYP2B1/2 mRNA levels by 
both compounds (close to significant, p=0.07) (Fig. 5D and 5E). These findings 
demonstrate that momfluorothrin induces CYP2B1/2 mRNA through CAR in Wistar rat 
hepatocytes and hence momfluorothrin is a CAR activator. This was also strongly 
supported by the in vivo study in CAR KO rats; where 3000 ppm momfluorothrin 
increased CYP2B1/2 mRNA in WT rats but not in CAR KO rats (Fig. 8A, Table 5).  
 
Hepatic CYP2B induction (Associative event) 
In Wistar male rats, hepatic CYP2B activity was induced 2.8-fold after 7 days 
treatment with 3000 ppm of momfluorothrin (Fig. 7C, Table 4). A marginal increase in 
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CYP2B activity to 1.2-fold of control was observed in male rats given 1500 ppm 
momfluorothrin for 7 days (Table 4). In addition, hepatic CYP2B1/2 mRNA levels in 
male rats given 3000 ppm momfluorothrin for 7 or 14 days were robustly increased by 
16 or 18 fold, respectively (Fig. 4, Table 4), suggesting that CYP2B mRNA levels 
would also have been significantly increased at lower doses of momfluorothrin. In 
females, increases in hepatic CYP2B activity were observed at momfluorothrin dose 
levels of 1500 and 3000 ppm after 7 days (Fig. 7C, Table 4) and at a dose level of 3000 
ppm after 14 days (Table 4).  
 
Liver hypertrophy (Associative event) 
 Treatment with momfluorothrin resulted in significant increases in liver weights 
associated with hepatocellular hypertrophy throughout the liver lobule (Table 4). In 
addition, increased smooth endoplasmic reticulum, characteristic of enzyme inducers 
(Ghadially, 1997), was observed in liver sections from male and female rats given a 
high 6000 ppm dose level of momfluorothrin for 13 weeks (ECHA, 2014).  
 By transmission electron microscopy, the treatment of male rats with 3000 ppm 
momfluorothrin for 7 and 14 days did not result in any apparent increase in numbers 
and size of peroxisomes. This confirms the results of the selected CYP mRNA analysis 
and the global gene expression studies that momfluorothrin is not PPARα agonist in rat 
liver (Fig. 4, Fig. 9, and Table 4).   
 
Altered gene expression specific to CAR activation (Key event #2) 
Activation of CAR in both the mouse and rat results in changes in the expression of 
a large number of genes involved in phase I and II xenobiotic metabolism, cell 
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proliferation, apoptosis and energy metabolism (Elcombe et al., 2014). Although studies 
in WT mice and CAR-KO mice have demonstrated that not all genes affected by PB are 
CAR-dependent, some of genes were only induced in WT mice, suggesting CAR 
specific genes. The altered genes by momfluorothrin treatment at 3000 ppm for 14 days 
overlapped with genes altered after 14-day treatment with NaPB as shown in this study 
(Okuda et al., 2017a). In addition, those by momfluorothrin also overlapped with genes 
altered after 7-day treatment with a CAR activator metofluthrin (1800 ppm) or NaPB 
(1000 ppm); i.e., CYP family 2, subfamily b; polypeptide 2 aldehyde dehydrogenase; 
aldo-keto reductase; UDP-glucuronosyltransferase; glutathione-S-transferase and 
epoxide hydrolase (Deguchi et al., 2009). Interestingly, CAR specific genes 
demonstrated by Ueda et al. (2002), those are also included CYP family 2, subfamily b; 
aldehyde dehydrogenase; and glutathione-S-transferase, also overlapped. These findings 
suggest that momfluorothrin alters gene expression specific to CAR. 
 
Increased cell proliferation (Key event #3) 
 The treatment of male and female Wistar rats with 1500 and 3000 ppm 
momfluorothrin for 7 days resulted in significant increases in replicative DNA synthesis 
(Fig. 7B, Table 4). Significant increases in replicative DNA synthesis were also 
observed in male and female Wistar rats given 3000 ppm momfluorothrin for 14 days 
(Table 4). However, the magnitude of the increase in replicative DNA synthesis after 14 
days was less marked than that observed after 7 days in both sexes (Fig. 6B, Table 4). 
This finding is consistent with previous studies with other mitogenic rodent liver CAR 
activators where short-term treatment results in a peak stimulation of hepatocyte 
labeling index values (Cohen and Arnold, 2011; Elcombe et al., 2014; Lake, 2009; Lake 
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et al., 2015; Yamada et al., 2009). Although the hepatocyte labeling index returns to 
control levels with continued treatment with the compound, the overall number of cell 
replications per animal is increased. This is because treatment with such chemicals 
causes a sustained increase in liver weight which results in an overall increase in the 
number and size of hepatocytes (Cohen and Arnold, 2011; Elcombe et al., 2014; Lake, 
2009). For example, in a study employing a stereological technique, an increase in the 
total number of hepatocytes per animal was observed in rats treated with PB for 12 
weeks (Carthew et al., 1998). Thus, although hepatocyte labeling index values may 
return to control levels after continued momfluorothrin treatment, the number of cell 
replications in treated animals continues to be enhanced due to the increase in the total 
number of hepatocytes per animal. The continued stimulation of cell proliferation may 
lead to tumor formation as a result of critical errors being produced during cell 
replication and/or enhanced proliferation of spontaneously initiated pre-neoplastic 
hepatocytes (Cohen and Arnold, 2008; Schulte-Hermann et al., 1983).  
Furthermore, momfluorothrin increased replicative DNA synthesis in WT rats 
(Tables 4 and 5), but not in CAR KO rats (Table 5), demonstrating that CAR activation 
is required for momfluorothrin-increased hepatocellular proliferation. 
 
Clonal expansion leading to altered hepatic foci (Key event #4) 
The treatment of male and female Wistar rats with momfluorothrin for 2 years 
resulted in liver tumor formation. In addition to the formation of liver tumors, the 
chronic treatment of male and female rats with 3000 ppm momfluorothrin also resulted 
in significant increases in eosinophilic hepatocellular foci (Table 1).   
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Liver adenoma/carcinoma (Key event #5) 
 The incidences of the total number of animals with hepatocellular adenomas and/or 
carcinomas of the 0, 200, 500, 1500 and 3000 ppm groups were 2, 0, 4, 12 and 33% for 
males, and 0, 0, 2, 2 and 10% for females, respectively (Table 1). Treatment with 3000 
ppm momfluorothrin significantly increased the incidence of hepatocellular adenoma in 
both sexes and of hepatocellular carcinoma in male rats. The combined incidence of 
hepatocellular adenoma and carcinoma was significantly increased in male and female 
rats given 3000 ppm momfluorothrin, with a non statistically significant increase being 
observed in male rats given 1500 ppm momfluorothrin. Therefore, the incidences of 
hepatocellular adenoma, carcinoma, and combined in males given 1500 and 3000 ppm 
momfluorothrin were equivalent to or higher than the maximum incidence of the 
historical background; and the combined incidence of female rats given 3000 ppm 
momfluorothrin was within the historical background incidence, while incidence of 
carcinoma was equivalent to the maximum incidence of the historical background. 
Overall, treatment with momfluorothrin in rats for 2 years produced hepatocellular 
tumors in males at 1500 and 3000 ppm and in females at 3000 ppm. The no tumorigenic 
dose levels (no observed effect levels for tumors) in male and female rats were 
established at 500 ppm and 1500 ppm, respectively.  
 
3. Concordance of dose-response relationships 
The present MOA study was performed with momfluorothrin doses used in the 
2-year bioassay. As shown in Fig. 7, the effects of momfluorothrin on CYP2B enzyme 
induction, hypertrophy (liver weight), and cell proliferation (replicative DNA synthesis) 
showed similar dose-dependency. In particular, in males and females at 3000 ppm, those 
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effects were significantly increased and corresponded with the tumor inducing dose 
(Table 6). In addition to the 7-day study, increases in hepatocyte hypertrophy and 
relative liver weights were also observed at 1500 ppm and above in both male and 
female Wistar rats after treatment for 52 weeks or longer (ECHA, 2014). 
In males at 1500 ppm, the increased incidence of liver tumor was equivocal; not 
statistically significant, but equivalent to or higher than the maximum incidence of the 
historical background in male Wistar rats. Thus 1500 ppm in males appeared to be 
borderline for tumor production. The increased relative liver weights and hepatocellular 
proliferation observed in rats given 1500 ppm momfluorothrin correlated with the 
observed tumor formation (Table 6). The treatment of male Wistar rats with 1500 ppm 
momfluorothrin did not result in a significant increase in CYP2B enzyme activity (Fig. 
7C), hence the dose response between tumor formation and CYP2B induction was not 
completely matched (Table 6). However, there were 16-18 fold increases in CYP2B1/2 
mRNA levels in male Wistar rats given 3000 ppm momfluorothrin for 7 and 14 days 
(Table 4), which suggest that some increase in CYP2B1/2 mRNA levels would have 
been observed in male rats treated with 1500 ppm momfluorothrin. Moreover, 
hepatocellular tumor incidence at this dose level was only marginally increased (not 
statistically significant) and increased incidences of eosinophilic hepatocellular foci 
were only observed at 3000 ppm in both sexes (Table 1). The tumor incidence data 
suggests that the potency for CAR activation by momfluorothrin would be less at a dose 
level of 1500 ppm than at 3000 ppm.  
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Table 6. Temporality and dose-response for MOA key events related to male and female Wistar rat liver tumors. 
  Temporal 
  
 
 
 
 
 
 
 
 
 
 
Dose (ppm) 
Key Event #1 
CAR activation 
Key Event #2 
A altered gene 
expression 
specific to 
CAR 
activation 
Key Event #3 
Increased cell 
proliferation 
a
 
 
Key Event 
after recovery 
 
Key Event #4 
Clonal expansion 
leading to altered 
hepatic foci  
Key Event #5 
Liver  
adenomas/ 
carcinomas 
 
 Biomarker 
CYP2B 
mRNA and 
activity 
Associative 
Event: Increased 
liver weight and 
hypertrophy 
 
Time points 7, 14 days 
7, 14 days 
13, 52, 104 
weeks 
14 days 7, 14 days 
7 days after 7 
days treatment 
104 weeks 104 weeks 
 
Males        
 
WT 
200 - - ND - ND - - 
 500 - - ND - ND - - 
 
1500 - c 
+ 
(7D -104W) 
ND 
+ 
(7D) 
d ND -  
+ 
(104W) 
e 
 
3000 
+ 
(7 - 14D) 
+ 
(7D- 104W) 
+ 
(14D) 
+ 
(7 - 14D) 
- 
+ 
(104W) 
+ 
(104W) 
 CAR KO 3000 
b 
- - ND - ND ND ND 
 Females        
 WT 200 - - ND - ND - - 
 
500 - 
+ 
(52W) 
ND - ND - - 
 
1500 
+ 
(7D) 
+ 
(7D - 104W) 
ND 
+ 
(7D) 
d ND - - 
 
3000 
+ 
(7 - 14D) 
+ 
(7D - 104W) 
ND 
+ 
(7 - 14D) 
ND 
+ 
(104W) 
+ 
(104W) 
WT: wild type Wistar rats. CAR KO: CAR Knock out rats. + with shadow indicates effect present at indicated time points of the treatment. - indicates effect absent at indicated time points of the treatment. 
ND indicates No data. 
a: Although hepatocyte labeling index values, determined as BrdU labeling index, may return toward control levels with continued momfluorothrin treatment for more than 14 days, the number of cell 
replications in treated animals appeared to be enhanced due to the increased total number of hepatocytes per animal. In this Table, “Increased cell proliferation” means “Increased total cell proliferation”. 
b: The key/associative events in the CAR KO rat study were determined after 7 days treatment.  
c: Increased PROD activity in males at 1500 ppm was a marginal change without statistical significance (1.2-fold of control). 
d: Cell proliferation in both sexes at 1500 ppm were determined only after 7 days treatment.  
e: The combined incidence of hepatocellular adenoma and carcinoma was increased in male rats given 1500 ppm momfluorothrin, with a non-statistically significant. As the incidences of hepatocellular 
adenoma, carcinoma, and combined in males given 1500 ppm momfluorothrin were equivalent to or higher than the maximum incidence of the historical background, 1500 ppm was concluded as tumor 
inducing dose level. Table is adapted from Okuda et al., (2017a). 
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Indeed, the present data demonstrate that the effects on hepatocellular proliferation, 
CYP2B enzyme induction and liver hypertrophy were less marked in male Wistar rats 
given 1500 compared to 3000 ppm momfluorothrin (Table 4). 
In females given 1500 ppm momfluorothrin, while the early events such as the 
increased hepatic CYP2B activity, relative liver weight and hepatocellular proliferation 
were observed after 7 days of treatment, liver tumor formation was not increased 
(Table 6).  
 
4. Temporal Association 
If a key event (or events) is an essential element for carcinogenesis, it must precede 
the appearance of the tumors. Data are available for the effect of treatment of male and 
female Wistar rats with momfluorothrin at various time points ranging from 7 days to 2 
years (Table 6). The treatment of male and female Wistar rats with momfluorothrin for 7 
days resulted in an induction of CYP2B enzymes. Cell proliferation, assessed as the 
hepatocyte labeling index, was increased in male and female Wistar rats given 
tumorigenic dose levels of momfluorothrin for 7 and 14 days. Momfluorothrin produced 
increases in liver hypertrophy (assessed both by morphology and as increases in liver 
weight) at a number of early time points and also at later time points. Examination of 
liver sections from the momfluorothrin two year bioassay revealed increases in altered 
cell foci at the tumorigenic dose level of 3000 ppm in male and female Wistar rats. 
Three of 51 male Wistar rats given 1500 ppm momfluorothrin also had altered cell foci 
(Table 1). As altered foci are the precursor lesions for subsequent tumor formation in 
rodent liver (Elcombe et al., 2014), it is considered that the liver foci developed before 
the appearance of liver tumors. Overall, there is a logical temporal sequence for all key 
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and associative events in momfluorothrin-induced liver tumor formation, in which all 
key and associative events precede tumor formation (Table 6).  
In females at 1500 ppm, while the early events such as the increased hepatic 
CYP2B activity, relative liver weights and hepatocellular proliferation were observed 
after 7 days of treatment, liver tumor was not increased (Table 6). Incidence of the 
eosinophilic hepatocellular foci was observed at 1500 ppm with a non-statistically 
significant increase and higher than average but less than highest incidence of historical 
control (Table 1). These finding suggest that 1500 ppm momfluorothrin induced the 
early events but not later events promoting from foci to tumor in female Wistar rats.      
 
5. Strength, consistency and specificity of association of key events and tumor 
response 
As mentioned above, the effects of momfluorothrin on key and associative events at 
early phase of treatment correlated with the dose-relationship for liver tumor formation. 
Furthermore there is a logical temporal sequence for all key and associative events in 
momfluorothrin-induced liver tumor formation, in which all key and associative events 
precede tumor formation.  
The effects of momfluorothrin on liver weight, hepatocellular hypertrophy and 
CYP2B enzyme induction after 7 days of treatment were shown to be reversible after 7 
days of cessation of treatment. Therefore, effects of short term treatment with 
momfluorothrin on the liver are reversible, which is consistent with the known hepatic 
effects of other mitogenic rodent liver CAR activators (LeBaron et al., 2013, 2014; 
Osimitz and Lake, 2009; Tinwell et al., 2014; Yamada et al., 2014). 
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6. Biological plausibility and coherence 
The proposed MOA for liver tumor formation by momfluorothrin involves 
activation of CAR which results in the key event of increased cell proliferation. 
Associative events include induction of CYP2B enzymes and liver hypertrophy. 
Prolonged treatment results in the formation of altered hepatic foci and liver tumors 
(Table 6). This MOA is similar to that of several other non-genotoxic rodent liver 
carcinogenic agents which are CAR activators (Currie et al., 2014; Lake et al., 2015; 
LeBaron et al., 2013, 2014; Osimitz and Lake, 2009; Tinwell et al., 2014; Yamada et al., 
2009, 2014). 
As described earlier, the key events for the MOA for momfluorothrin-induced rat 
liver tumor formation comprise CAR activation, increased cell proliferation and the 
development of altered hepatic foci as these constitute necessary steps in the MOA. The 
induction of CYP2B enzymes and liver hypertrophy comprise associative events and 
represent reliable markers of CAR activation. The role of CAR in CYP2B enzyme 
induction and increased hepatocellular proliferation by momfluorothrin was also 
demonstrated in cultured rat hepatocytes using the RNAi technique and in an in vivo 
study in CAR KO rats. These findings are consistent with those of metofluthrin 
(Deguchi et al., 2009; Yamada et al., 2009). 
 
7. Other modes of action 
Liver tumors can be produced in rodents by both genotoxic and non-genotoxic 
agents (Cohen and Arnold, 2011; Williams, 1997). Momfluorothrin is clearly not 
genotoxic, being negative in a variety of in vivo and in vitro genotoxicity assays (Ames 
test, in vitro chromosomal aberration test, in vitro gene mutation assay, UDS assay and 
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mouse micronucleus test)(ECHA, 2014). Liver tumors can be produced in rodents by 
various non-genotoxic MOAs including cytotoxicity, activation of CAR, activation of 
PPAR, porphyria, statins and hormonal perturbation (Cohen, 2010; Cohen and Arnold, 
2016; Holsapple et al., 2006; Klaunig et al., 2003; Meek et al., 2003). In the general 
toxicity studies, utilizing both histopathology and electron microscopy techniques, there 
was no evidence of hepatocellular toxicity (e.g. necrosis, fatty liver), peroxisome 
proliferation, porphyria, statin-like alterations, increased iron deposition or any evidence 
of hormonal perturbation. In addition, as shown in Fig. 4, unlike effects on CAR, gene 
expression profiling analysis studies demonstrated no marked alterations in either 
PPAR, AhR or PXR signaling. Overall, it is considered that the hepatic effects of 
momfluorothrin in the rat and subsequent liver tumor formation are mediated by 
activation of CAR.  
Although some oxidative stress related genes were increased in the global gene 
expression analysis (Okuda et al., 2017a), the direct endpoints related to oxidative stress 
have not examined. Oxidative stress in the liver after administration of PB or 
metofluthrin was assessed by MDA as an indicator of lipid peroxidation, as well as total 
and reduced glutathione as a measure of antioxidant capacity. However, no evidence 
was obtained for the involvement of oxidative stress in PB or metofluthrin-induced rat 
liver tumor formation (Deguchi et al., 2009). In the liver of rats treated with 
momfluorothrin, there was no histopathological evidence indicating increased oxidative 
stress, such as degenerative findings like necrosis and fibrosis. Though oxidative stress 
has been implicated as an important factor in the carcinogenesis process for both 
genotoxic and nongenotoxic mechanisms (Klaunig and Kamendulis, 2004), it was not 
identified as a key event for liver tumor formation by PB and other CAR activators 
 53 / 120 
 
(Elcombe et al., 2014). 
 
8. Uncertainties, inconsistencies, and data gaps 
No data have been obtained for effects of momfluorothrin treatment on apoptosis 
and inhibition of gap junctional intercellular communication, which were identified as 
an associative event and an associative event/modulating factor, respectively, in the 
MOA for PB-induced rodent liver tumor formation proposed by Elcombe et al. (2014). I 
consider that, since decreased apoptosis or inhibition of gap junctional intercellular 
communication are not key events (Elcombe et al., 2014), these data gaps do not alter 
the overall conclusion regarding the postulated MOA for momfluorothrin-induced rat 
liver tumors.  
 
9. Conclusions 
These data are considered adequate with a high degree of confidence to explain the 
development of liver tumors in rats following chronic administration of momfluorothrin. 
As described above, a plausible MOA for momfluorothrin-induced rat liver tumor 
formation have been established as CAR activated MOA, with a strong 
dose-dependency and temporal consistency, that is similar to certain other 
non-genotoxic mitogenic rodent liver carcinogenic agents which are CAR activators 
including PB and metofluthrin (Currie et al., 2014; Kushida et al., 2016; Lake et al., 
2015; LeBaron et al., 2013, 2014; Osimitz and Lake, 2009; Tinwell et al., 2014; 
Yamada et al., 2014, 2015). Alternative MOAs for momfluorothrin-induced rat liver 
tumor formation have been excluded. Therefore, the answer to question 1 “Is the WoE 
sufficient to establish a MOA in animals?” in the IPCS framework is Yes. 
 
 54 / 120 
 
 
 
 
 
 
 
 
 
Chapter 2 
 
Evaluation of human relevancy for rat hepatocellular tumors induced by 
momfluorothrin 
 
2-1 
Utility analysis of novel humanized chimeric mice with human hepatocytes for human 
risk assessment treated with CAR activator, NaPB 
 
 
 
  
 55 / 120 
 
Introduction 
 
In the previous chapter, it was identified the MOA for momfluorothrin-induced rat 
liver tumors mediated by CAR activation pathway. CAR is the molecular target of CAR 
activators (i.e. PB, metofluthrin, and momfluorothrin) and activation of this receptor is 
an essential for the rodent liver tumor development (Okuda et al., 2017a; Yamada et al., 
2015; Elcombe et al., 2014; Huang et al., 2005; Wei et al., 2000; Yamamoto et al., 
2004). A number of studies using PB have shown that the CAR is also present in the 
human liver and that the receptor can be activated by various drugs and chemicals 
(Elcombe et al., 2014; Molnar et al., 2013; Moore et al., 2003), but CAR-mediated liver 
non-genotoxic carcinogenesis is not generally considered to be human-relevant (Cohen, 
2010; Elcombe et al., 2014; Holsapple et al., 2006; Lake, 2009) because the key species 
difference is that while PB stimulates replicative DNA synthesis in rodent hepatocytes, 
such effects are not observed in cultured human hepatocytes (Elcombe et al., 2014; 
Hirose et al., 2009; Lake, 2009; Parzefall et al., 1991). In addition, there is no clear 
evidence for PB-associated liver cancer risk in humans based on epidemiological data 
from a large number of clinical studies including long-term therapeutic treatment of 
epileptics (Friedman et al., 2009; La Vecchia & Negri, 2014). Based on these data, 
evaluation utilizing the ILSI/IPCS framework (Boobis et al., 2006) demonstrates that 
the MOA for PB-induced liver carcinogenicity is not relevant for humans (Cohen, 2010; 
Elcombe et al., 2014; Holsapple et al., 2006; Lake, 2009). 
In addition to the use of hepatocyte culture systems, if the key species difference in 
PB-stimulated hepatocyte replicative DNA synthesis could be evaluated in an in vivo 
experiment, the results obtained would provide important data for the human risk 
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assessment of CAR activators like PB. One possible in vivo system for such a study is 
the use of humanized mice (Foster et al., 2014; Kitamura and Sugihara, 2014). Recently, 
mice with human hepatocyte chimeric livers have been produced by transplanting 
human hepatocytes into albumin enhancer/promoter-driven urokinase-type plasminogen 
activator-transgenic severe combined immunodeficient (uPA/SCID) mice with liver 
disease (Tateno et al., 2004; 2013). The host mouse hepatocytes are replaced with 
human hepatocytes in the livers of the chimeric mice to the degree indicated by the 
replacement index, which is the occupancy ratio of the human hepatocyte area to the 
total (human and mouse) area on histological sections. In some cases, the replacement 
index in these mice can be as high as 96%. The transplanted human hepatocytes express 
mRNA for a variety of human drug-metabolizing enzymes and transporters, in a manner 
similar to that of the donor liver (Tateno et al., 2004; 2013). Chimeric mouse livers 
constructed with human hepatocytes contain a small percentage of mouse hepatocytes 
and mouse hepatic sinusoidal cells (mainly Kupffer cells, endothelial cells, and stellate 
cells). Human hepatocytes have been shown to cooperate with mouse hepatic sinusoidal 
cells in liver functions such as enzyme induction (Tateno et al., 2004) and viral 
infection (Mercer et al., 2001). Interestingly, human hepatocytes in the livers of 
chimeric mice are also susceptible to growth enhancing activities. The treatment of 
chimeric mice with human growth hormone (hGH) increases the repopulation speed and 
the replacement index of transplanted human hepatocytes, as determined by increased 
replicative DNA synthesis and the up-regulation of GH-related signalling molecules 
(Masumoto et al., 2007). Furthermore, partial hepatectomy also enhances hepatocellular 
proliferation in chimeric mice (personal communication, Dr. Chise Tateno). These 
 57 / 120 
 
findings thus suggest that transplanted human hepatocytes in chimeric mice are 
responsive to hepatocyte mitogens.  
The objective of the present study was to examine whether studies with chimeric 
mice with humanized liver could provide further support for previous evaluations of the 
MOA for PB-induced rodent liver tumor formation which have concluded that this 
mitogenic MOA is not relevant for humans (Cohen, 2010; Elcombe et al., 2014; 
Holsapple et al., 2006; Lake, 2009). The effects of NaPB-treatment on key and 
associative events observed at the early phase of treatment were compared in CD-1 
mice, Wistar Hannover rats, and in chimeric mice with humanized liver. 
These obtained experimental and analytical data have already been published from 
Toxicological Sciences (Yamada et al., 2014). 
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Materials and Methods 
 
Test chemical.  
Momfluorothrin and metofluthrin were provided by Sumitomo Chemical Co., Ltd. 
(See chapter 1). NaPB (Lot No. TLQ4248; purity, 98.0%) and human epidermal growth 
factor (hEGF; AF-100-15), Peprotech (EC, London, United Kingdom) were purchased 
from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). 
 
Animals and husbandry.  
All experiments were performed in accordance with The Guide for Animal Care 
and Use of Sumitomo Chemical Co., Ltd.; The Guide for Biosafety of Sumitomo 
Chemical Co., Ltd.; or with the ethical approval of the PhoenixBio Ethics Board.  
 
CD-1 mouse and Wistar Hannover rat.  
Male Crlj:CD1(ICR) mice aged 9 weeks and male HarlanRCCHanTM:WIST rats 
(WH rats) aged 9 weeks were purchased from Charles River Japan, Inc., Hino Breeding 
Center (Shiga, Japan) and Japan Laboratory Animals, Inc., Hanno Breeding Center 
(Saitama, Japan), respectively. The animal acclimatization and environmental conditions 
were same as chapter 1.  
 
Chimeric mouse.  
The in-life phase of the experiment using chimeric mice and SCID mice was 
performed at PhoenixBio Co., Ltd. (Higashihiroshima, Japan). Chimeric mice with 
human hepatocytes (PXB mouse®, PhoenixBio Co., Ltd) were produced as previously 
described (Tateno et al., 2004; 2013). Briefly, cryopreserved human hepatocytes (donor 
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ID: BD195) were purchased from BD Biosciences, Woburn, MA, USA. Human 
hepatocytes were transferred to homozygotic cDNA-uPA
+/+
/SCID mice aged 20-30 
days as donor cells for the chimeric mice because cells from young subjects are more 
responsive to stimulation of hepatocellular proliferation (Masumoto et al., 2007). For 
transplantation, vials of cryopreserved human hepatocytes (5-15 x 10
6
 cells/vial) were 
thawed and transplanted into 20-60 uPA/SCID mice (2.5 x 10
5
 viable cells/mouse). 
Since the human albumin (hAlb) concentration in mouse blood correlates well with the 
replacement index (Tateno et al., 2004), the hAlb concentration in the blood samples 
was measured to predict the replacement index of human hepatocytes in mouse livers. 
Chimeric mice have previously been shown to have almost confluent human 
hepatocytes at 64 days and 81 days after transplantation (Tateno et al., 2004). To reduce 
possible variation of background levels of replicative DNA synthesis, treatment with 
NaPB was commenced more than 70 days after transplantation (animal age 14-17 
weeks). Human hepatocytes in chimeric mice are considered to be deficient in GH 
because the human GH receptor is unresponsive to mouse GH (Souza et al., 1995). Due 
to a lack of human GH in chimeric mice, the chimeric mouse liver spontaneously 
becomes fatty in the human hepatocyte regions about 70 days after transplantation 
(Tateno et al., 2011). Therefore, to mimic the normal in vivo condition and to decrease 
steatosis, Alzet minipumps (Model 1002, Alzet Corporation, Palo Alto, CA, U.S.A.) 
containing recombinant human GH (Wako Pure Chemical Industries Ltd.), with a 
release rate of 2.05 µg/hr, were implanted in the subcutaneous tissue of mice under 
isoflurane anesthesia on the day prior to 7 days before the commencement of chemical 
treatment. The animals were housed in a clean room with HEPA filtered air. During the 
course of the study, the environmental conditions in the animal room were set to 
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maintain a temperature range of 18 - 28 °C and a relative humidity range of 30 - 80, 
with frequent ventilation and a 12 hour light (8:00 - 20:00)/ 12 hour dark (20:00 - 8:00) 
illumination cycle. A commercially available pulverized diet (CRF-1; Oriental Yeast 
Co., Ltd., Tokyo) containing vitamin C (300 mg/100g diet) and filtered tap water were 
provided ad libitum throughout the study. The animals were not fasted overnight prior to 
sacrifice. Mice were randomly assigned to each group based upon body weight and 
replacement indices, so that there was no significant difference in mean body weight 
and replacement indices among the groups. 
 
Design for study.  
In the hEGF study, the effects of hEGF treatment (150 μg/kg, 4 times per day, i.p., 
for 2 days) on human hepatocyte replicative DNA synthesis were determined in 
chimeric mice (5 animals/dose).  
The design of the NaPB study is summarised in Table 7. Male CD-1 mice and WH 
rats (8 animals/dose) were fed diets containing 0 (control), 500, 1000, 1500, or 2500 
ppm NaPB for 7 days. In previous bioassays, liver tumors were increased in a number 
of mouse strains at a NaPB dietary level of 500 ppm (IARC, 2001; Whysmer et al., 
1996) and at a dietary level of 1000 ppm in male mice of the low spontaneous tumor 
incidence C57BL/10J mouse strain (Jones et al., 2009). Therefore, dietary levels of 500 
and 1000 ppm were selected for this study. In addition, in order to evaluate the effects of 
higher doses of NaPB, dietary levels of 1500 and 2500 ppm were also investigated. In 
the dose setting study where chimeric mice (3 mice/dose) with less than a 70% 
replacement index were given NaPB at dose levels of 0, 1500, 2000, and 2500 ppm, one 
of three animals died at each of 2000 and 2500 ppm doses. Diets containing 0 (control) 
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or 1500 ppm were fed to chimeric mice (5 mice/dose) with more than a 70% 
replacement index for 7 days in the main study. However, 3 of 5 chimeric mice given 
1500 ppm NaPB also died. Replicative DNA synthesis and other data was thus only 
obtained from two animals at 1500 ppm. Therefore, additional chimeric mice fed diets 
containing 0 (control), 500, and 1000 ppm were investigated and the combined data 
from these two experiments were evaluated to obtain dose-response effects of NaPB in 
chimeric mice. SCID mice were treated with 0 (control) and 1500 ppm for comparison 
with the highest dose group in the chimeric mouse study. As significant increases in 
hepatocyte replicative DNA synthesis, determined as the hepatocyte labeling index, are 
observed transiently at the early phase of treatment with NaPB in rodents (Cohen and 
Arnold, 2011; Elcombe et al., 2014; Lake, 2009), a 7-day treatment period was selected 
for the present study. 
Mortality, body weight, and food consumption were monitored throughout the study. 
Alzet minipumps (Model 2001 in CD-1 and chimeric mice, Model 2ML1 in rats; Alzet 
Corporation) containing BrdU (Sigma Company, St Louis, MO, U.S.A.), with a release 
rate of 40 and 200 µg/hr, respectively, were implanted in the subcutaneous tissue of 
mice and rats, under anesthesia with diethyl ether or isoflurane on the day prior to 7 
days (2 days for the hEGF study) before the scheduled euthanasia. After the 7-day 
treatment period, blood was collected at euthanasia from all surviving animals from the 
abdominal aorta under diethyl ether anesthesia (CD-1 mice and WH rats) and from the 
heart under isoflurane anesthesia (chimeric mice and SCID mice) without prior fasting. 
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Table 7. Summary of study design of NaPB study. 
Animals CD-1 mice Wistar Hannover rats Chimeric mice 
a
 SCID mice 
Sex Male 
Age (weeks) 10 10 14 10-14 
Number of animals per dose 8 8 5 
b
 5 
NaPB dose levels (ppm) 0, 500, 1000, 1500, 2500 0, 500, 1000, 1500, 2500 0, 500, 1000, 1500 
c
 0, 1500 
Human GH treatment 
d
 No No Yes No 
Administration route In diet 
Administration period (days) 7 
Measurements
 e
 Body weight, food consumption, plasma concentration of PB, hepatic CYP2B activity (PROD activity), 
hepatocyte replicative DNA synthesis (BrdU labeling index), liver histopathology (light and electron 
microscopy), functional transcriptomic and metabolomic analyses, and selected gene expression determined by 
quantitative real-time polymerase chain reaction 
a: The range of replacement index with human hepatocytes in chimeric mice used in the present study was 73-90%. 
b: Control (0 ppm) group of chimeric mice consisted of 9 animals because data from two experiments were combined. 
c: Chimeric mice were not examined at 2500 ppm due to death in preliminary dose setting study. Data at 1500 ppm in chimeric mice is from two surviving 
animals. 
d: Due to a lack of human GH in chimeric mice, the chimeric mouse liver spontaneously becomes fatty in the human hepatocyte regions about 70 days after 
transplantation (Tateno et al., 2011). Therefore, to mimic the normal in vivo condition and to decrease steatosis, Alzet minipumps containing recombinant 
human GH were implanted in the subcutaneous tissue of mice on the day prior to 7 days before the commencement of NaPB treatment.  
e: Electron microscopy was only examined in chimeric mice, and functional transcriptomic and metabolomic analyses were not examined in SCID mice. 
Table is adapted from Yamada et al., (2014). 
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All organs and tissues from all animals were subjected to gross pathological 
examination. The liver of all animals was weighed under wet condition. Relative organ 
weight (organ weight to body weight ratio) was calculated on the basis of the body 
weight on the day of euthanasia. After necropsy, a piece of liver from all surviving 
animals was removed and stored in RNA stabilization solution (Life Technologies Co., 
Carlsbad, CA) at 4°C overnight. After that, the RNA stabilization solution was removed 
and these samples were moved to a deep freezer at –80°C for analysis for gene 
expression, whereas the rest of the liver tissue was processed for hepatic microsomal 
CYP enzyme activity, histopathology, and replicative DNA synthesis measurements. 
The blood samples were immediately centrifuged at 2150  g for 15 min at 4 °C and the 
plasma samples obtained were immediately extracted with a 3-fold volume of 
acetonitrile. The supernatants were stored at -80 °C until examined by liquid 
chromatography/mass spectrometry (LC/MS) analysis. 
 
Plasma concentration of PB.  
Chromatographic separation was performed by a CapcellPak C18 MG II column 
(35 x 3 mm, 3 µm, Shiseido). The mobile phase was A; 0.1% formic acid in water and 
B; acetonitrile delivered at a flow rate of 0.5 mL/min, and the gradient condition 
was %B = 5% (0 min) - 100% (5 min). MS data acquisition was accomplished in 
selected reaction monitoring mode (SRM) for PB (negative, m/z=231/188) with an 
atmospheric pressure chemical ionization interface using a TSQ Vantage (Thermo 
Fisher Scientific Inc.). Standard curves were obtained using NaPB. 
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Quantitative real-time PCR.  
CYP2B mRNA expression levels were determined in livers of all surviving animals 
from each model. Quantitative real-time PCR assays were performed as described 
chapter 1. The primer and probe sequences are listed in Table 3.  
 
Hepatic CYP enzyme activity. 
Liver postmitochondrial supernatant (S9) fractions were prepared and CYP2B 
activity was determined as PROD by fluorometric analysis using the specific substrate 
for CYP2B enzyme as shown chapter 1.  
 
Liver histopathology.  
Livers from all surviving animals were examined by light microscopy and 
transmission electron microscopy in described chapter 1. In addition, for chimeric mice, 
the right lateral lobe in the control and NaPB 1500 ppm groups was prefixed by 
perfusing 2.5% glutaraldehyde in 0.2 M phosphate buffer (pH 7.4) using a syringe for 2 
animals/group. Human hepatocyte-originated areas of these liver samples were cut into 
piece of less than 5 mm in thickness with a razor blade in 2.5% glutaraldehyde in 0.2 M 
phosphate buffer (pH 7.4).  
 
Hepatocyte replicative DNA synthesis.  
The cell proliferation rate was evaluated as replicative DNA synthesis determined 
as the BrdU labeling index. BrdU labeling was analyzed microscopically in a blinded 
manner with more than 2000 hepatocytes per animal being evaluated in CD-1 mice and 
WH rats. An image analysis system was used to evaluate the BrdU labeling indices of 
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human hepatocytes in chimeric mice and mouse hepatocytes in SCID mice. Glass slides 
were scanned at 20x magnification using Olympus VS120 virtual slide scanning system 
(Olympus, Tokyo, Japan) and Definiens Tissue Studio software (Definiens, Munich, 
Germany). Areas consisting of human hepatocytes (without inflammation or necrosis) 
were selected manually with at least one area from each of 4 lobes (lateral left lobe, 
lateral right lobe, medial right lobe and medial left lobe) and custom-made image 
analysis algorithms were applied to the digital slides to automatically detect and 
quantify the number of positively and negatively stained hepatocytes. The total number 
of evaluated human hepatocytes was more than 8,000 per chimeric or SCID mouse.  
 
Statistical analysis. 
 See chapter 1. 
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Results 
 
Summary of the effect of NaPB treatment on some selected endpoints are shown in 
Table 8. In this study data are expressed on a plasma PB µg/mL basis, rather than on a 
ppm dietary dose level basis, in order to permit a clearer evaluation of species 
differences in the effects of NaPB treatment. 
 
Mortality and Body weight 
One CD-1 mouse given 2500 ppm NaPB, three chimeric mice given 1500 ppm 
NaPB and one control chimeric mouse died during treatment (data not shown), 
suggesting that the maximum tolerated dose of NaPB in chimeric mice is lower than 
that in both CD-1 mice and WH rats. A statistically significant suppression of final body 
weight with concomitant lower food consumption was observed in WH rats treated with 
NaPB 2500 ppm (data not shown). The body weights of the two surviving chimeric 
mice given 1500 ppm NaPB were similar to those of control chimeric mice.  
 
NaPB Intake and Plasma Levels 
NaPB intakes, calculated from food consumption and NaPB concentration in diet 
data, and plasma PB levels were increased in a dose-dependent manner in CD-1 mice, 
WH rats, and chimeric mice (Table 8). While mean plasma PB levels were similar in 
CD-1 mice and WH rats, chimeric mice had the highest plasma PB levels at each NaPB 
dietary level. The ranges of PB plasma levels in chimeric mice given 500, 1000 and 
1500 ppm NaPB were 17.3-35.9 µg/mL, 40.1-149.4 µg/mL, 86.3-146.1 µg/mL, 
respectively. 
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Table 8. Summary for responses to NaPB treatment in CD-1 mice, Wistar Hannover rat, chimeric mice and SCID mice 
 
 CD-1 mice  WH rats  Chimeric mice  SCID mice 
(ppm) 500 1000 1500 2500  500 1000 1500 2500  500 1000 1500 
c 
 1500 
Overall NaPB intake 
(mg/kg/day) 
59 120 180 250  30 60 85 120  69 150 230  220 
Plasma NaPB levels 
(µg/mL) 
12 30 43 70  8.0 20 35 61  27 75 120  43 
Absolute liver weight 
a
 1.2 1.5 1.5 1.6  1.1 1.2 1.2 1.2  1.2 1.2 1.2  1.4 
Relative liver weight 
a
 1.2 1.4 1.5 1.7  1.1 1.2 1.2 1.3  1.1 1.1 1.1  1.5 
PROD activity 
a
 4.4 5.4 6.4 6.4  22 27 24 20  6.8 14 14  13 
CYP2B mRNA levels 
a
 43 59 61 62  170 220 230 250  6.9 7.4 11  160 
Hepatocyte hypertrophy 
b
 8/8 8/8 7/7 7/7  8/8 6/8 8/8 8/8  1/5 1/5 2/2  5/5 
BrdU labeling index 
a
 5.7 13 18 17  3.9 4.6 4.7 4.4  1.9 1.3 1.4  4.6 
a: Vales are presented as fold control at each dose level. Values statistically significantly different from control (p<0.05) are presented with bold red. 
b: Results are presented as number of animals with findings per number of animals examined. 
c: Data at 1500 ppm in chimeric mice which is from two surviving animals was not analyzed statistically. 
Table is adapted from Yamada et al., (2014).
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In this paper most data are expressed on a plasma PB µg/mL basis, rather than on a 
ppm dietary dose level basis, in order to permit a clearer evaluation of species 
differences in the effects of NaPB treatment. 
 
Liver weight and morphology 
Statistically significant, dose-dependent increases in absolute liver weight were 
observed in CD-1 mice, WH rats and chimeric mice (Table 8). In the highest NaPB dose 
group of chimeric mice, the increase was not statistically significant owing to the small 
number of animals that survived. Statistically significant, dose-dependent increases in 
relative liver weight were observed in CD-1 mice and WH rats, whereas NaPB only 
produced small increases in relative liver weight in chimeric mice (Table 8). The 
chimeric mouse livers were characterized morphologically (Fig. 10A) and histologically 
(Fig. 10B) with respect to the extent of chimerism, in that they contained both white and 
red areas (Fig. 10A). The white areas consisted of human hepatocytes and were easily 
distinguishable from the areas of mouse hepatocytes. The red nodules that were 
distributed sporadically in the livers of chimeric mice represent colonies of 
transgene-deleted host hepatocytes, as reported previously (Sandgren et al., 1991). In 
the human hepatocytes of chimeric mice treated with 1500 ppm NaPB, cytosolic 
glycogen areas were decreased and the size of the cells was slightly increased in the 
centrilobular area (Figs. 10C and 10D). These hepatic changes suggest that 
human-originated hepatocytes exhibited slight hypertrophic changes after NaPB 
treatment, the effect being less marked than that observed in WH rats and CD-1 mice 
(data not shown).  
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Figure 10. Liver gross pathology and histology in chimeric mice. Photographs present gross (A) 
and histological (B) appearance of livers of control chimeric mice, with h-heps and m-heps 
representing human hepatocytes and mouse hepatocytes, respectively. Histopathology (C, D) and 
ultrastructure (E, F) of human hepatocyte-originated areas of chimeric mice given 0 (C, E) and 1500 
ppm (D, F) NaPB are also presented. Centrilobular hepatocellular hypertrophy (D) and proliferation 
of SER (F) was observed in NaPB treated chimeric mice. Figure is adapted from Yamada et al., 
(2014). 
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Electron microscopic evaluation was only conducted in chimeric mice treated with 
1500 ppm NaPB, which supported the light microscopic changes, since an increase of 
SER was observed in the human-originated hepatocytes (Figs. 10E and 10F).  
 
Hepatic CYP2B gene expressions and enzyme activity 
CYP2B mRNA levels by NaPB were significantly increased in three animal models, 
but the increase was much less in chimeric mice than in CD-1 mice and WH rats (6.9, 
7.4, and 11.3-fold at 500, 1000, and 1500 ppm in chimeric mice, respectively) (Fig. 
11A). While PROD activity was increased in a dose-dependent manner up to 1000 ppm 
NaPB (mean plasma PB level 75.2 µg/mL) in chimeric mice. The maximum fold 
change of the PROD activity in chimeric mice (approximately 14-fold control) was 
between WH rats (approximately 20~27-fold control) and CD-1 mice (approximately 
5~6-fold control) (Fig. 11B). In the highest NaPB dose group of chimeric mice the 
increase was not statistically significant owing to the small number of animals that 
survived. 
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Figure 11. Effect of NaPB treatment on CYP2B mRNA expression (A) and hepatic 
7-pentoxyresorufin O-depentylase (CYP2B marker) activity (B) in CD-1 mice, WH rats and 
chimeric mice. The mRNAs were determined by quantitative real-time PCR and presented as fold 
control (0 ppm) levels. Mean values from 5-9 animals except for data at 1500 ppm in chimeric mice 
which is from two surviving animals are presented as fold control at each dose level. Values 
significantly different from control (0 ppm) are: *p<0.05 and **p<0.01. Figure is adapted from 
Yamada et al., (2014). 
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Replicative DNA Synthesis 
In CD-1 mice and WH rats, replicative DNA synthesis was significantly increased 
by treatment with NaPB at all dose levels (Figs. 12A). While human hepatocytes in 
chimeric mice did not show any significant increase in replicative DNA synthesis at 
NaPB dose levels of 1000 and 1500 ppm, even though plasma PB levels (75±46.9 and 
116 (86 and 146) µg/mL for 1000 and 1500 ppm) were higher than those of the highest 
2500 ppm CD-1 mouse group (70.2±48.7 µg/mL) (Figs. 12A). Interestingly, treatment 
with hEGF significantly increased replicative DNA synthesis in human hepatocytes of 
chimeric mice (Fig. 12B). Thus, these data clearly demonstrate that transplanted human 
hepatocytes in chimeric mice maintain the mitogen signaling. All individual labeling 
index values in NaPB-treated chimeric mice were within the control range (2.4~10.7 %) 
except for one outlier given 500 ppm NaPB (16.6 %), suggesting that the marginally 
higher values in NaPB-treated chimeric mice are not biologically significant (Fig. 12C). 
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Figure 12. Effect of NaPB treatment on replicative DNA synthesis in CD-1 mice, WH rats, and 
chimeric mice. (A) Mean values are presented as fold control at each dose level, (B) the effect of 
hEGF treatment (150 µg/kg x 4 times /day, i.p., 2 days) on hepatocyte replicative DNA synthesis in 
chimeric mice, (C) Individual values (triangles) with mean value of the dose groups (bars) in 
chimeric mice. The shaded area represents the control range. While at 500 ppm mean value of all 
animals examined is 7.2%, it is 5.3% when one outlier (16.6%) is excluded. Values significantly 
different from control (0 ppm) are: **p<0.01. In chimeric mice, no values were significantly 
different (p>0.05) from control (0 ppm) irrespective of inclusion of one outlier. Figure is adapted 
from Yamada et al., (2014). 
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Discussions 
 
The treatment of rats and mice with NaPB results in activation of CAR leading to a 
pleiotropic response, which includes liver hypertrophy, induction of CYP2B and other 
xenobiotic metabolising enzymes, increased hepatocyte proliferation and ultimately in 
the development of altered hepatic foci and liver tumors. A number of evaluations have 
identified the key and associative events in the MOA for NaPB-induced rodent liver 
tumor formation (Cohen, 2010; Elcombe et al., 2014; Holsapple et al., 2006; Lake, 
2009). The pivotal key event in this MOA is the stimulation of hepatocyte replicative 
DNA synthesis. Although NaPB produces cell proliferation in rat and mouse 
hepatocytes, other models are refractory to the mitogenic effects of this compound 
(Elcombe et al., 2014; Lake, 2009). While NaPB induces replicative DNA synthesis in 
rodent hepatocytes both in vivo and in vitro, the absence of an increase in cultured 
human hepatocytes suggests that the MOA for NaPB-induced rodent liver tumor 
formation is qualitatively not plausible for humans (Elcombe et al., 2014).  
   Apart from in vitro studies with cultured human hepatocytes, another possible model 
for investigating the effects of NaPB and related compounds on human hepatocytes is to 
utilise immunocompromised mice with humanized livers. The uPA/SCID model used in 
this investigation (Tateno et al., 2004; 2013) has been used in a number of toxicity and 
metabolism studies to predict human response to drugs and other compounds (Foster et 
al., 2014; Kitamura and Sugihara, 2014). The data obtained in this study clearly 
demonstrate that transplanted human hepatocytes in chimeric mice are responsive to 
hEGF, a hepatocyte mitogen. 
CAR is present in human liver and can be activated by drugs and other compounds, 
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including NaPB (Elcombe et al., 2014; Molnar et al., 2013; Moore et al., 2003). In the 
present study the treatment of chimeric mice with human hepatocytes with NaPB 
resulted in significant dose-dependent increases in mRNA levels of known CAR-target 
genes including CYP2B6. There was also a good correlation between plasma PB levels 
and CYP2B6 mRNA levels (Fig. 11A), confirming the functional viability of CAR 
signalling in the human hepatocytes of the chimeric mice. The higher induction of 
PROD activity in chimeric mice compared to CD-1 mice may be due in part to 
contamination by mouse hepatocytes, because unlike the mRNA studies, the method for 
examination of PROD activity used in this study does not distinguish between human 
and mouse hepatocytes and PROD is not generally used as a marker of CYP2B6 (Fig. 
11B). Although the lower responsiveness of chimeric mice to NaPB compared to CD-1 
mice and WH rats may be partially attributable to lower expression of CAR mRNA, 
species differences in the signalling of CAR target genes are likely contribute to 
differences in potency for each response, especially for hepatocellular proliferation.   
In keeping with previous studies, the treatment of CD-1 mice and WH rats with 
NaPB resulted in significant increases in hepatocyte replicative DNA synthesis. 
Treatment with NaPB also increased replicative DNA synthesis in hepatocytes of SCID 
mice (Table 8). In contrast to CD-1 mice, WH rats and SCID mice, the treatment of 
chimeric mice with NaPB did not result in any increase in hepatocyte replicative DNA 
synthesis (Table 8). 
The plasma levels of PB observed in chimeric mice with human hepatocytes after 
treatment with NaPB were higher than those obtained in both CD-1 mice and WH rats. 
In addition, the dose setting study established that that NaPB dietary levels of >1500 
ppm could not be administered to chimeric mice with human hepatocytes. It is therefore 
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considered that the lack of effect of NaPB on replicative DNA synthesis in chimeric 
mice with human hepatocytes is an accurate finding, as higher dose levels of NaPB 
could not be examined in this study. Moreover, the plasma levels of PB observed in 
chimeric mice with human hepatocytes in this study following treatment with 1000 and 
1500 ppm NaPB were around 3-5 fold higher than those reported in human subjects 
given therapeutic doses of 3-6 mg/kg where plasma levels ranged from 10-25µg/mL 
(Monro, 1993).  
In conclusion, some of the key and associative events in the MOA for 
NaPB-induced rodent liver tumor formation are observable in human liver. However, 
the key species difference is that although NaPB is a mitogenic agent in rat and mouse 
liver, no such effect is observed in human liver. To date, the major evidence that NaPB 
is not mitogenic in human liver comes from studies with cultured human hepatocytes 
(Elcombe et al., 2014; Hirose et al., 2009; Lake, 2009). The data obtained in this study 
provides additional in vivo evidence for a marked species difference in the mitogenic 
effects of NaPB. 
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Chapter 2 
 
Evaluation of human relevancy for rat hepatocellular tumors induced by 
momfluorothrin 
 
2-2 
Analysis for the human relevancy for rat hepatocellular tumors induced by 
momfluorothrin using cultured rat and human hepatocytes and humanized chimeric 
mice  
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Introduction 
 
In chapter 1, the MOA for rat hepatocellular tumor formation by momfluorothrin 
was evaluated based on the ILSI/IPCS framework (Boobis et al., 2006, 2008; 
Sonich-Mullin et al., 2001). This MOA study demonstrated that momfluorothrin 
produces liver hypertrophy, induces hepatic CYP2B enzymes and increases 
hepatocellular proliferation in WT rats but not in CAR KO rats (Okuda et al., 2017a). 
Moreover, alternative MOAs for momfluorothrin-induced rat hepatocellular tumor 
formation including cytotoxicity, activation of PPARα, accumulation of iron, statin-like 
effects and hormonal perturbation have been excluded (Okuda et al., 2017a). These 
findings demonstrate that the MOA for hepatocellular tumor formation by 
momfluorothrin is the same as that of some other nongenotoxic mitogenic CAR 
activators such as metofluthrin, a close structural analogue to momfluorothrin (Yamada 
et al., 2009), and PB (Elcombe et al., 2014). 
Since increased hepatocellular replicative DNA synthesis is considered to be the 
critical key event for CAR-mediated hepatocellular tumorigenesis (Elcombe et al., 
2014), it is important to determine whether the test compound has a mitogenic effect on 
human hepatocytes or not. 
Based on the MOA for momfluorothrin-produced rat hepatocellular tumors being 
the same as that for PB and metofluthrin (Okuda et al., 2017a), the MOA for 
momfluorothrin-induced rat hepatocellular tumors is also postulated as not relevant in 
humans. To confirm this hypothesis, species differences in mitogenic effects of 
momfluorothrin and its major metabolite Z-CMCA 
((Z)-(1R,3R)-3-(2-cyanoprop-1-enyl)-2,2-dimethylcyclopropanecarboxylic acid) were 
examined using both cultured rat and human hepatocytes in the present study. In 
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addition to the cultured human hepatocytes, the effects of momfluorothrin and 
metofluthrin on replicative DNA synthesis in human hepatocytes of chimeric mice were 
examined in this chapter. 
These obtained experimental and analytical data were published from the Journal of 
Toxicological Sciences (Okuda et al., 2017b). 
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Materials and Methods 
 
All animal experiments were performed in accordance with The Guide for Animal 
Care and Use of Sumitomo Chemical Co., Ltd.; and all experiment using human 
hepatocyte preparations were performed in accordance with The Guide for Biosafety of 
Sumitomo Chemical Co., Ltd.  
 
Test chemicals 
   The chemicals were obtained from the following manufacturers: momfluorothrin 
(See chapter 1), metofluthrin (See chapter 1), and Z-CMCA (Lot No. SK0712171; 
Purity 99.8 %), Sumitomo Chemical Co., Ltd. (Tokyo, Japan); NaPB (Lot No. 
KLM4036, purity 98.0%), Wako Pure Chemical Industries, Ltd. (Osaka, Japan); human 
recombinant hepatocyte growth factor (hHGF), Sigma-Aldrich (St. Louis, USA); hEGF 
(See chapter 2-1), Peprotech (EC, London, United Kingdom). 
 
Cultured hepatocytes study 
Hepatocytes 
Rat hepatocytes were isolated by a two-step perfusion procedure from 
HarlanRccHanTM:WIST male rats aged 10 weeks (purchased from Japan Laboratory 
Animals, Inc., Hanno Breeding Center, Saitama, Japan) (Hirose et al., 2009; Yamada et 
al., 2015). Viability (range 80 - 92 %) was determined by trypan blue exclusion. Rat 
hepatocytes were cultured in William’s medium E (GIBCO) (See chapter 2 in materials 
and methods) 
Cryopreserved human hepatocytes for the cell culture study were obtained from 
Celsis IVT (MD, USA). A total of ten different human hepatocyte preparations were 
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used in this study. Information on the donors of the hepatocyte preparations used is 
presented in Table 9. Human hepatocytes were thawed and plated according to the 
supplier's instructions. Briefly, cryopreserved hepatocytes were thawed at 37 ºC for 1 
min, transferred into 20 mL in William’s medium E containing 2 mM L-glutamine, 0.1 
µM bovine insulin, 1 µM dexamethasone, 10 mM nicotinamide, 0.2 mM L-ascorbic 
acid, 0.5 ng/ml hEGF, and 10 % (v/v) fetal bovine serum. The supernatant was 
discarded and the hepatocytes were resuspended in Williams’ medium E containing the 
additions described above (Yamada et al., 2015).  
For assays of CYP2B mRNA induction, rat hepatocytes were plated at a density of 
4.0 x 10
5
 cells/well per 2 mL of medium containing the above additions in 6-well plates 
(two rats) and 6.0 x 10
4
 cells/well per 500 µL of medium containing the above additions 
in 24-well plates (3 rats); human hepatocytes were plated at a density of 3.0 x 10
5
 
cells/well per 500 µL of medium containing the above additions in 24-well plates. For 
assays of replicative DNA synthesis, rat and human hepatocytes were plated at a density 
of 1.0 x 10
4
 and 3.5 x 10
4
 cells/well per 100 µL of medium containing the above 
additions, respectively, in 96-well plates. All tissue culture plates were coated with 
collagen I (AsahiTechnoGlass, Japan) and the hepatocytes were cultured at 37 ºC in a 
humidified incubator under an atmosphere of 95 % air/5 % carbon dioxide (Hirose et al., 
2009; Yamada et al., 2015).  
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Table 9. Details of human hepatocyte preparations studied 
 
Human hepatocytes were obtained from Celsis (Bioreclamation IVT) (# 1-10) or BD Biosciences (# 11-13). 
Endpoints determined: A: cell viability; B: BrdU incorporation; C: CYP2B mRNA expression; and D: liver 
weight. 
CVA: Cerebrovascular attack; ICH: Intracerebral hemorrhage; MVA: Motor vehicle accident; RD: Respiratory 
Disease.  
Table is adapted from Okuda et al., (2017b). 
 
 
# Lot 
No. of  
donor 
Gender Ethnicity Age  Smoking Alcohol Drug 
use 
Cause of 
death 
Experiments Endpoints 
determined 
1 BHL Male Caucasian 28 Yes Yes Yes ICH-Stroke Cultured cell 
studies 
A, B 
2 ETA Female Caucasian 80 Yes No 
reported 
No 
reported 
CVA A, B 
3 CDP Male Caucasian 58 No No No CVA B 
4 DOO Male Caucasian 57 No No No Anoxia; 
2nd to CVA 
B, C 
5 FCL Female Hispanic 10 
months 
No No No 
reported 
Anoxia/ 
drowning 
B, C 
6 IPH Female Caucasian 52 No No No Anoxia; 
2nd to CVA 
7 LLA Male Caucasian 26 Yes Yes No 
reported 
Head trauma 
8 LMP Female Caucasian 38 Yes Yes No 
reported 
CVA 
9 MMM Female Caucasian 3 No No No Drowning 
10 QOQ Male Caucasian 66 Yes Yes No CVA 
11 BD87 Male Caucasian 2 No No 
reported 
No MVA Chimeric 
mouse studies 
B, C, D 
12 BD85 Male African  
American 
5 No No 
reported 
Yes 
(RD) 
Anoxia 
13 BD195 Female Hispanic 2 No No 
reported 
No MVA 
 83 / 120 
 
Chemical treatment 
For assays of CYP2B induction, rat and human hepatocytes were incubated for 48 
hours in medium containing the above additions and in William’s medium E containing 
2 mM L-glutamine, 0.7 µM bovine insulin, and 50 µM hydrocortisone hemisuccinate 
(Sigma-Aldrich), respectively. Rat and human hepatocytes were treated with 
momfluorothrin (1, 5, 10, 50, 100, 500, and 1000 µM), Z-CMCA (5, 10, 50, 100, 500, 
and 1000 µM) and NaPB (500 (rat hepatocytes only) and/or 1000 µM). As a vehicle 
control, all media were supplemented with dimethyl sulfoxide (DMSO) at a final 
concentration of 0.1% (v/v). The medium was changed after 4 hours (only rat) from 
plating the hepatocytes and then at 24 hour intervals. For each concentration of the test 
chemicals the assays were run in three wells of 6-well plates or in three wells of 24-well 
plates. Studies were performed with hepatocyte preparations from five rats and seven 
human donors, and each assay was performed on a different isolation and donor (not 
pooled).  
For assays of replicative DNA synthesis, rat and human hepatocytes were incubated 
for 48 hours in medium same as CYP2B induction assay. Rat and human hepatocytes 
were treated with momfluorothrin (1, 5, 10, 50, 100, 500, and 1000 µM), Z-CMCA (5, 
10, 50, 100, 500, and 1000 µM for rat hepatocytes; 5, 100, 500, and 1000 µM for human 
hepatocytes), NaPB (500 and 1000 µM) and recombinant hHGF (10 and 100 ng/mL), 
which is a well-known growth factor stimulating replicative DNA synthesis in 
hepatocytes (Hirose et al., 2009; Runge et al., 1999; Yamada et al., 2015). In the media 
containing momfluorothrin, Z-CMCA, NaPB and hHGF for rat and human hepatocytes, 
0.5 ng/mL EGF was added to activate DNA synthesis (Runge et al., 1999). As a vehicle 
control, all media were supplemented with DMSO at a final concentration of 0.1% (v/v). 
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The medium was changed after 4 hours (only rat) from plating the hepatocytes and then 
at 24 hour intervals. Assays were run in either eight or twelve wells of 96-well plates at 
each concentration of the test chemicals and hHGF. Studies were performed with 
hepatocyte preparations from eight rats and ten human donors.  
 
Determination of DNA synthesis 
The extent of DNA synthesis was determined by measuring BrdU (Sigma-Aldrich) 
incorporation into DNA over a 24 hour period in humidified incubator at 37 ºC, using a 
Cell Proliferation ELISA BrdU (chemiluminescent) kit (Roche, Germany) as previously 
described (Hirose et al., 2009; Yamada et al., 2015). BrdU (100 µM) was added to the 
medium at the point of the medium change after 24 hours of chemical treatment. After 
24 hours treatment with the test chemicals and hHGF in medium containing BrdU, 
hepatocytes were dried and fixed according to the kit supplier's instructions. The 
luminescences of the samples were measured with a luminometer (EnVision, 
PerkinElmer), with the measurements being conducted by Sumika Technoservice 
Corporation (Hyogo, Japan). The proliferation rate was calculated from the luminescent 
intensity compared to untreated controls. 
 
CYP2B mRNA expression analysis by quantitative real-time PCR 
At the end of the treatment period, the medium was removed and the hepatocytes 
(approximately 2-4 x 10
5
 cells) were washed with PBS (pH 7.4). Total RNA preparation 
and quantitative real-time PCR assays for rat CYP2B1/2 and human CYP2B6 were 
performed as described chapter 1. In addition, levels of rat and human GAPDH mRNA 
were determined as internal controls. The primer and probe sets are listed in Table 3.  
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Cell viability analysis 
Under the same conditions as for the experiments for replicative DNA synthesis, 
cell viability was analyzed employing a Cell counting kit (Dojindo laboratories, 
Kumamoto, Japan) as previously described (Yamada et al., 2015). Briefly, rat and 
human hepatocytes were incubated in 96-well plates at a density of 1.0 x 10
4
 and 3.5 x 
10
4
 cells/well, respectively, for 48 hours with medium containing momfluorothrin (10, 
50, 100, and 1000 µM), Z-CMCA (50, 100 and 1000 µM), NaPB (1000 µM), or hHGF 
(10 and 100 ng/mL). As a vehicle control, all media were supplemented with DMSO at 
a final concentration of 0.1 % (v/v). The medium was changed after 4 hours (only rat) 
from plating the hepatocytes and then at 24 hour intervals. After the test chemical 
treatment, medium containing the Cell counting kit reagent was added to each well and 
the cells incubated for 4 hours at 37 °C. The plates were read using a microplate reader 
(SH-1000 Lab, Corona Electric, Ibaraki, Japan) at a wavelength of 450 nm. The 
measurements were conducted by Sumika Technoservice Corporation. Cell viability 
was determined with two preparations each of cultured rat and human hepatocytes. 
Since an initial screening conducted in two preparations each of cultured rat and 
human hepatocyte (Lot numbers of human hepatocytes were BHL and ETA) showed 
that momfluorothrin and Z-CMCA had no marked cytotoxicity, cell viability was not 
examined in other preparations. 
 
Humanized chimeric mice study 
The in-life phase of the experiments using chimeric mice was performed at 
PhoenixBio Co., Ltd. (Hiroshima, Japan). Three experiments focused on the cell 
proliferation effects on human hepatocytes were conducted with chimeric mice 
 86 / 120 
 
produced by individual three donors (donor ID; BD87, BD85, and BD195, see Table 9). 
Briefly, cryopreserved human hepatocytes from donors BD85, BD87 and BD195 were 
purchased from BD Biosciences, Woburn, MA, USA. Human hepatocytes from donors 
BD85 and BD87 were transferred to homozygotic cDNA-uPA
+/+
/SCID mice and 
hepatocytes from donor BD195 were transferred to hemizygotic cDNA-uPA
wild/+
/SCID 
mice (which is an improved type from homozygotic SCID mice) (Tateno et al., 2015) 
aged 20-30 days as donor cells for the chimeric mice because cells from young subjects 
are more responsive to stimulation of hepatocellular proliferation (Masumoto et al., 
2007). The range of replacement indices in chimeric mice used in Experiments I (BD87), 
II (BD85) and III (BD195) was estimated as 75-89%, 90-100%, and 81-98%, 
respectively. The highest dose level in the 2-year rat study in which hepatocellular 
tumors were increased by treatment with momfluorothrin and metofluthrin was used in 
this study; namely 3000 ppm for momfluorothrin, 1800 ppm for metofluthrin. The dose 
level of momfluorothrin was originally set at 3000 ppm in Experiment I, but it was 
decreased to 1100 ppm in Experiments II and III due to animal deaths (Days 2 and 3, 
commencement of treatment is counted as Day 0) in Experiment I. Since 1500 ppm 
momfluorothrin, which was the 2
nd
 higher dose level in the 2-year rat study, also 
showed a palatability problem with similar degree as 3000 ppm in the preliminary dose 
setting study (date not shown), 1100 ppm was used in the Experiments II and III. 
Chemical intake (170 and 146 mg/kg/day in Experiment II and III, respectively; Table 
10) was higher than or equivalent to those at tumorigenic dose levels in males in the rat 
2-year bioassay; 73 mg/kg/day at 1500 ppm and 154 mg/kg/day at 3000 ppm. The oral 
route was selected because it is one of the potential exposure routes for humans and to 
be consistent with the exposure route utilized in the momfluorothrin and metofluthrin 
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rat carcinogenicity and MOA studies. Diet containing the test compounds was provided 
to animals ad libitum for 7 days due to a clear enhancement of hepatocellular 
proliferation having been observed in rats in previous studies after 7-days treatment 
with momfluorothrin (see chapter 1) and metofluthrin (Yamada et al., 2009). 
 
Mortality, body weight, and food consumption were monitored throughout the study. 
Alzet minipumps (Model 2001; Alzet Corporation) containing BrdU (Sigma Company, 
St Louis, MO, U.S.A.), with a release rate of 40 µg/hr were implanted in the 
subcutaneous tissue of mice, under anesthesia with isoflurane on the day prior to 7 days 
before the scheduled euthanasia. After the 7-day treatment period, blood collection, 
gross pathological examination, liver weight, and storage of liver sample were 
conducted with same methods as chapter 2-1. 
 
Quantitative real-time PCR.  
CYP2B mRNA expression levels were determined in livers of all surviving animals 
from each model. Quantitative real-time PCR assays were performed as described 
chapter 1. The primer and probe sequences are listed in Table 3.  
 
Hepatic CYP enzyme activity. 
Liver postmitochondrial supernatant (S9) fractions were prepared and CYP2B 
activity was determined as PROD by fluorometric analysis using the specific substrate 
for CYP2B enzyme as shown chapter 1.  
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Liver histopathology.  
Livers from all surviving animals were examined by light microscopy and 
transmission electron microscopy in described chapter 1. Human hepatocyte-originated 
areas of these liver samples were cut into piece of less than 5 mm in thickness with were 
fixed in 10 % neutral buffered formalin.  
 
Hepatocyte replicative DNA synthesis.  
The cell proliferation rate was evaluated as replicative DNA synthesis described in 
chapter 2-1. The total number of evaluated human hepatocytes was more than 8,000 per 
chimeric mouse.  
 
Statistical analysis. 
    See chapter 1. 
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Results 
 
Cultured hepatocytes study 
To compare the responses between rat and human hepatocytes to treatment with 
momfluorothrin, Z-CMCA, NaPB and hHGF, the data obtained for cell viability, 
CYP2B mRNA expression, and replicative DNA synthesis for both species are 
presented in Figs. 13-15.  
 
Cell viability 
With respect to cell viability (Fig. 13), none of the treatments produced a marked 
reduction in formazan production by dehydrogenase enzymes. Some small decreases in 
formazan production were observed in rat hepatocytes treated with 1000 M 
momfluorothrin and human hepatocytes treated with 1000 M Z-CMCA. The increases 
in formazan production at some concentrations of momfluorothrin, NaPB and hHGF 
observed in rat hepatocytes may be due to increased metabolic activity as a result of 
either CYP2B enzyme induction and/or increased replicative DNA synthesis. 
 
CYP2B gene expression 
Treatment with 1000 M NaPB produced a less marked effect on CYP2B mRNA 
levels in human than in rat hepatocytes (Fig. 14). The effects of momfluorothrin and 
Z-CMCA on CYP2B mRNA levels were also less marked in human than in rat 
hepatocytes, with Z-CMCA only producing an induction of CYP2B mRNA levels in rat 
hepatocytes.  
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Figure 13 Effect of hHGF, NaPB, momfluorothrin and Z-CMCA on cell viability in cultured 
rat and human hepatocyte. Rat and human hepatocytes were treated with hHGF (10 and 100 
ng/ml), NaPB (1000 μM), momfluorothrin (10-1000 μM) and Z-CMCA (50-1000 μM) for 48 hours 
and cell viability was determined by a cell counting kit. Results are presented as individual values  
expressed as percentage of control at each concentration of hHGF, NaPB, momfluorothrin and 
Z-CMCA in each of two rat and human hepatocyte preparations. Figure is adapted from Okuda et al., 
(2017b). 
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Figure 14. Effect of NaPB, momfluorothrin and Z-CMCA on CYP2B mRNA expression in 
cultured rat and human hepatocytes. Rat and human hepatocytes were treated with NaPB (500 
and 1000 μM), momfluorothrin (1-1000 μM) or Z-CMCA (5-1000 μM) for 48 hours and rat 
CYP2B1/2 and human CYP2B6 mRNA levels determined by quantitative real-time PCR. Results are 
presented as mean  SD (n=2-5 rat and n=1-7 human hepatocyte preparations) expressed as 
percentage of control at each concentration of NaPB, momfluorothrin or Z-CMCA. Values 
significantly different from control (DMSO only treated) are: * p<0.05 and ** p<0.01 in rat 
hepatocytes; and 
##
 p<0.01 in human hepatocytes. Figure is adapted from Okuda et al., (2017b). 
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Replicative DNA synthesis 
The treatment of rat hepatocytes with 100 ng/mL hHGF and human hepatocytes 
with 10 and 100 ng/mL hHGF resulted in significant increases in replicative DNA 
synthesis, thus confirming the functional viability of the rat and human hepatocyte 
preparations used in these studies to treatment with a mitogenic agent (Fig. 15). In rat 
hepatocytes, significant increases in replicative DNA synthesis were observed after 
treatment with 500 and 1000 M NaPB and 5 and 10 M momfluorothrin, whereas 
replicative DNA synthesis was reduced by treatment with 100-1000 M 
momfluorothrin. In contrast to the effects observed in rat hepatocytes, the treatment of 
human hepatocytes with 500 and 1000 M NaPB and 1-1000 M momfluorothrin had 
no significant increase in replicative DNA synthesis. Treatment with 5-1000 M 
Z-CMCA had no significant effects on replicative DNA synthesis in either rat or human 
hepatocytes. 
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Figure 15. Effect of hHGF, NaPB, momfluorothrin and Z-CMCA on replicative DNA synthesis 
in cultured rat and human hepatocytes. Rat and human hepatocytes were treated with hHGF (10 
and 100 ng/ml), NaPB (500 and 1000 μM), momfluorothrin (1-1000 μM) or Z-CMCA (5-1000 μM) 
for 48 hours and replicative DNA synthesis determined by BrdU incorporation over the last 24 hours 
of culture. Results are presented as mean  SD (n=3-8 rat and n=5-10 human hepatocyte 
preparations) expressed as percentage of control at each concentration of hHGF, NaPB, 
momfluorothrin or Z-CMCA. Values significantly different from control (DMSO only treated) are: * 
p<0.05 and ** p<0.01 in rat hepatocytes; and 
#
 p<0.05 and 
##
 p<0.01 in human hepatocytes. Figure is 
adapted from Okuda et al., (2017b). 
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Chimeric mice study 
A summary of the data obtained is presented in Table 10. In three separate 
experiments, chimeric mice transplanted with human hepatocytes from different donors 
were treated for 7 days with diets containing 1800 ppm metofluthrin (average chemical 
intake, 239-285 mg/kg/day) and with 1100 or 3000 ppm momfluorothrin (average 
chemical intake, 146-170 mg/kg/day for 1100 ppm; 410 mg/kg/day for 3000 ppm).  
As described in the Method section, the dose level of momfluorothrin was changed 
in Experiments II and III due to animal interim deaths (Days 2 and 3, commencement of 
treatment is counted as Day 0) in Experiment I. Regarding metofluthrin, while no 
mortality was observed in Experiments I and III, two of five animals treated with 1800 
ppm metofluthrin were found dead during the early phase of treatment (Days 2 and 3) in 
Experiment II. The average chemical intakes in these 7-day studies were higher than 
those observed at tumourigenic dose levels administered to male rats in the 2-year 
bioassays, which were 38 and 78 mg/kg/day for 900 and 1800 ppm mg/kg/day 
metofluthrin, respectively, and 73 and 154 mg/kg/day for 1500 and 3000 ppm 
momfluorothrin, respectively. With the exception of interim deaths due to suppressed 
food consumption possibly resulting from neurotoxicity during the early phase of 
treatment (data not shown), no severe toxic effects were observed during the study.  
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Table 10. Summary of findings in chimeric mouse study 
Experiment I. Donor ID; BD87 
Groups Control 
Metofluthrin 
1800 ppm 
Momfluorothrin 
3000 ppm 
hEGF 
600 μg/kg 
Number of animals examined 5 5 3a 5 
Average Chemical intake (mg/kg/day) 0 272 410 0.6 
Liver weight Absolute (g) 2.78±0.36 2.89±0.32 2.36±0.51 2.75±0.25 
(fold control) (1.00) (1.04) (0.85) (0.99) 
Liver weight Relative (g/body weight x 100) 13.47±1.80 14.43±2.13 11.83±1.43 13.78±1.13 
(fold control) (1.00) (1.07) (0.88) (1.02) 
Replicative DNA synthesis in human hepatocytes (%) 11.59±6.77 4.63±2.03 6.71±6.76 21.18±9.03 
(fold control) (1.00) (0.40) (0.58) (1.83) 
Human CYP2B6 mRNA (% of control average) 100±18.93 111±11.90 136±17.70* 124±18.24 
(fold control) (1.00) (1.11) (1.36) (1.24) 
Mouse Cyp2b10 mRNA (% of control average) 100±33.49 424±118.90** 1692±600.04* 154±26.17* 
(fold control) (1.00) (4.24) (16.92) (1.54) 
     
Experiment II. Donor ID; BD85 
Groups Control 
Metofluthrin 
1800 ppm 
Momfluorothrin 
1100 ppm 
hEGF 
600 μg/kg 
Number of animals examined 5 3b 8 5 
Average Chemical intake (mg/kg/day) 0 239 170 0.6 
Liver weight Absolute (g) 2.30±0.20 2.14±0.08 2.17±0.21 2.53±0.23 
(fold control) (1.00) (0.93) (0.94) (1.10) 
Liver weight Relative (g/body weight x 100) 11.71±0.79 11.72±0.68 11.19±0.67 12.94±0.87* 
(fold control) (1.00) (1.00) (0.96) (1.11) 
Replicative DNA synthesis in human hepatocytes (%) 7.44±4.00 5.23±3.08 4.59±1.61 12.22±5.51 
(fold control) (1.00) (0.70) (0.62) (1.64 ) 
Human CYP2B6 mRNA (% of control average) 100±12.90 137±14.75* 93±12.77 135±41.88 
(fold control) (1.00) (1.37) (0.93) (1.35) 
Mouse Cyp2b10 mRNA (% of control average) 100±55.9 281±136.5* 266±105.9** 112±27.2 
(fold control) (1.00) (2.81) (2.66) (1.12) 
     
Experiment III. Donor ID; BD195 
Groups Control 
Metofluthrin 
1800 ppm 
Momfluorothrin 
1100 ppm 
hEGF 
600 μg/kg 
Number of animals examined 5 8 5 5 
Average Chemical intake (mg/kg/day) 0 285 146 0.6 
Liver weight Absolute (g) 2.63±0.40 2.61±0.34 2.61±0.40 3.21±0.39* 
(fold control) (1.00) (0.99) (0.99) (1.22) 
Liver weight Relative (g/body weight x 100) 11.98±1.59 12.44±1.68 11.94±1.21 14.94±2.00* 
(fold control) (1.00) (1.04) (1.00) (1.25) 
Replicative DNA synthesis in human hepatocytes (%) 8.37±4.53 5.01±1.76 4.55±1.32 15.46±5.61 
(fold control) (1.00) (0.60) (0.54) (1.85) 
Human CYP2B6 mRNA (% of control average) 100±14.79 121±19.78* 86±16.29 120±29.02 
(fold control) (1.00) (1.21) (0.86) (1.20) 
Mouse Cyp2b10 mRNA (% of control average) 100±26.9 305±96.6** 191±14.1** 122±55.5 
(fold control) (1.00) (3.05) (1.91) (1.22) 
 
Results are presented as mean±SD, and values in parenthesis are fold change of control. Values significantly different 
from control are: * p<0.05 and ** p<0.01. a: For the momfluorothrin group of the experiment I, since five of eight 
animals found dead during treatment, group mean was evaluated in survived three animals. b: For the metofluthrin 
group of the experiment II, since two of five animals were found dead during treatment, group mean was evaluated in 
survived three animals. Table is adapted from Okuda et al., (2017b).
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CYP2B gene expression 
Under these study conditions, increased levels of CYP2B6 mRNA were observed in 
human hepatocytes, but the effects were relatively weak, being 1.1-1.4 fold of control in 
animals given 1800 ppm metofluthrin and 1.4 fold of control in animals given 3000 
ppm momfluorothrin. Although serum or liver concentrations of the test chemicals were 
not examined in the present study, significant increases in Cyp2b10 mRNA expression 
mouse hepatocytes (Table 10) demonstrated that treatment with metofluthrin or 
momfluorothrin significantly stimulated CAR in the mouse hepatocytes of the chimeric 
mice.  
 
Replicative DNA synthesis 
Under these conditions, treatment with metofluthrin or momfluorothrin did not 
result in any increases in replicative DNA synthesis of human hepatocytes (Table 10, 
Fig. 16A). However, as a positive control, hEGF treatment increased replicative DNA 
synthesis in human hepatocytes (Fig. 16A and 16B) though statistical significance was 
not observed due to the small number of animals examined (Table 10, Fig. 16A). When 
the data from all three experiments were combined, statistically significant increased 
replicative DNA synthesis was observed in the hEGF group (Fig. 16B). The BrdU 
labelling index was only determined in human hepatocytes and not in mouse 
hepatocytes in which the rate of replicative DNA synthesis was high even in controls 
(Fig. 17C and 17D), and thus it was difficult to compare between control and treatment 
animals. The cause of the high spontaneous DNA synthesis in the mouse hepatocytes is 
unclear but may be related to induced synthesis of DNA and/or hepatocyte damage by 
expression of uPA with consequent regeneration. 
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Figure 16. Effect of metofluthrin, momfluorothrin and hEGF on replicative DNA synthesis in 
human hepatocytes of chimeric mice. Replicative DNA synthesis as determined by BrdU labeling 
index is presented for individual (A) and average (B) of three experiments in chimeric mice from 
three different donors. Results are presented as mean  SD (A, n=3-8 mice per experiment per 
group; B, n=3 experiments per group). Figure is adapted from Okuda et al., (2017b). 
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Figure 17. Liver histology and DNA synthesis in chimeric mice.  
(A) Hematoxylin and eosin staining of appearance of livers of the control chimeric mice, with h-heps 
and m-heps representing human hepatocytes and mouse hepatocytes, respectively. (B-D) 
Immunohistochemistory for BrdU in the control animal (serial section of figure 17A (B), human 
hepatocytes area in the control animal (C) and human hepatocytes area in the hEGF treatment group 
(D). Scale bars are 100 m. Figure is adapted from Okuda et al., (2017b). 
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Discussions 
 
The stimulation of replicative DNA synthesis via CAR activation is the critical key 
event in the proposed MOA for momfluorothrin-induced rat liver tumor formation, as 
demonstrated by CAR KO rat study, CAR knockdown hepatocyte study using RNAi 
and hepatic global gene expression analysis (Okuda et al., 2017a). Therefore, effects of 
momfluorothrin and its major metabolite Z-CMCA on CYP2B mRNA induction and 
replicative DNA synthesis were examined in cultured rat and human hepatocyte 
preparations and in human hepatocytes of chimeric mice in the present study. 
Cyp2B is well-known as an associative event but not a key event for hepatocellular 
tumorigenesis related to CAR activation (Elcombe et al., 2014). Induction of total 
cytochrome P450 content and individual subfamily enzymes generally correlate poorly 
with carcinogenicity (Elcombe et al., 2002). Thus, Cyp2B is a biomarker for CAR 
activation, but the increases in Cyp2B levels do not correlate with the extent of cell 
proliferation. The treatment of rat and human hepatocytes with 1000 µM NaPB 
significantly increased CYP2B mRNA levels, demonstrating that under the 
experimental conditions employed in this study the cultured hepatocytes maintain 
enough CAR signaling functions to be able to respond to treatment with CYP2B 
enzyme inducers. 
hHGF is a well-known growth factor which is known to stimulate replicative DNA 
synthesis in hepatocytes (Runge et al., 1999; Yamada et al., 2015; Hirose et al., 2009). 
In the present study, hHGF increased replicative DNA synthesis in rat and human 
hepatocytes in a concentration-dependent manner. These results confirmed the 
functional viability of the rat and human hepatocyte preparations used in this study to 
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the effect of a known hepatocyte mitogen. 
Though momfluorothrin concentrations in rat liver have not been determined, 
plasma concentrations of momfluorothrin and Z-CMCA were determined in rats treated 
with momfluorothrin at 3000 ppm in the diet for 3 and 7 days. The plasma concentration 
of momfluorothrin was around 0.3 µM at both time points, and the concentration of 
Z-CMCA was approximately 10-fold higher than that of momfluorothrin (unpublished 
data).  
Since test chemical concentrations in the liver are expected to be more than 
2~10-fold higher than plasma concentrations based on findings of the momfluorothrin 
metabolism study (ECHA, 2014), the concentration range used in the present study 
(1~1000 µM for momfluorothrin, 5~1000 µM for Z-CMCA) would cover these 
expected concentrations in the liver. The treatment of rat hepatocytes with 1000 M 
momfluorothrin and human hepatocytes with 1000 M Z-CMCA resulted in slight 
decreases in formazan production, suggesting that high concentrations of 
momfluorothrin or Z-CMCA could be toxic to rat or human hepatocytes. However, the 
toxic effects observed at high concentrations in vitro does not appear to occur in vivo, as 
no hepatotoxic effects, such as necrosis, were observed in in vivo rat studies at doses up 
to the maximum tolerated dose (MTD) (ECHA, 2014; Okuda et al., 2017a). Thus, these 
findings suggest that the plasma concentrations of these chemicals in the 
carcinogenicity study with momfluorothrin were less than 1000 M. 
The treatment of rat hepatocytes with 500 and 1000 µM NaPB significantly 
increased replicative DNA synthesis consistent with previous findings (Hirose et al., 
2009). Replicative DNA synthesis in rat hepatocytes was significantly increased by 
treatment with 5 and 10 M momfluorothrin to 1.6- and 1.8- fold control, respectively. 
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However, the treatment of rat hepatocytes with 5-1000 M Z-CMCA had no statistically 
significant effect on replicative DNA synthesis, suggesting that momfluorothrin is likely 
the causative agent for rat liver tumor production rather than its major metabolite 
Z-CMCA. 
For human hepatocytes, in contrast to hHGF, replicative DNA synthesis was not 
increased by treatment with 500 and 1000 M NaPB, 1-1000 M momfluorothrin or 
5-1000 M Z-CMCA in the present study. The lack of effect of NaPB on replicative 
DNA synthesis in cultured human hepatocytes is consistent with previous findings 
(Hirose et al., 2009; Yamada et al., 2015; Parzefall et al., 1991). In keeping with the 
properties of the prototypic CAR activator PB, two closely structurally related 
pyrethroid insecticides metofluthrin (Yamada et al., 2015; Hirose et al., 2009) and 
momfluorothrin (present study) were demonstrated not to stimulate replicative DNA 
synthesis in cultured human hepatocytes. In addition, no stimulation of replicative DNA 
synthesis by NaPB in human hepatocytes has already been demonstrated in vivo in the 
study utilizing chimeric mice with human hepatocytes (Yamada et al., 2014). The 
present study demonstrated that momfluorothrin and metofluthrin did not increase in 
vivo human hepatocyte replicative DNA synthesis in chimeric mice employing 
hepatocytes from three different donors. Thus, correlation can be made between the 
findings in the human cells in the chimeric mice and the effects utilizing human cells in 
vitro compared to rodent cells. 
 
Human applicability of the proposed mode of action 
In terms of the human relevance of an animal carcinogenic MOA there are three 
questions to consider (Boobis et al., 2006) before reaching a conclusion (See Fig. 1). As 
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described in chapter 1, the postulated MOA is similar to that of certain other 
non-genotoxic agents which are CAR activators including that of a close structural 
analogue metofluthrin (Yamada et al., 2009). Alternative MOAs for 
momfluorothrin-induced rat liver tumour formation have been excluded. Thus, a 
plausible MOA for momfluorothrin-induced rat liver tumour formation has been 
established, and therefore, the answer to question 1 is yes. In assessing the relevance of 
animal MOA data to humans, a concordance table has been suggested as being of 
considerable value (Boobis et al., 2006). Such a table is presented in Table 11. This 
includes not only the data for the effects of momfluorothrin in the rat, but also the 
available data for humans. 
A number of studies have shown that CAR is present in human liver and that this 
receptor can be activated by drugs and other compounds (Moore et al., 2003). Hence, it 
is probable that at high doses momfluorothrin could activate CAR in human liver. 
Treatment with momfluorothrin increased CYP2B6 mRNA levels in human hepatocytes 
(Fig. 14). Thus, at high doses momfluorothrin has the potential to activate CAR and 
induce CYP2B enzymes in human liver.  
Studies in human subjects given anticonvulsant drugs (which induce hepatic CYP 
enzymes) have shown that prolonged treatment with high doses can increase liver size 
in humans, which is associated with liver hypertrophy and increased smooth 
endoplasmic reticulum (Aiges et al., 1980, Pirttiaho et al., 1978). Thus, by comparison 
with the effects of such anticonvulsant drugs, at high doses momfluorothrin has the 
potential to produce hypertrophy in human liver.         
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Table 11. Comparison of key and associative events on MOA for liver tumorigenesis of 
momfluorothrin in rats and humans (Table is adapted from Okuda et al., (2017b)). 
 
As the stimulation of replicative DNA synthesis is the critical key event in the 
proposed MOA for momfluorothrin-induced rat hepatocellular tumor formation (Okuda 
et al., 2017a), the effect of momfluorothrin on replicative DNA synthesis has been 
studied in cultured rat and human hepatocytes (Fig. 15). Using hepatocyte cultures, 
increases in replicative DNA synthesis following treatment with hHGF were observed 
in both rat and human hepatocytes. However, increased replicative DNA synthesis 
following momfluorothrin treatment was only observed in rat hepatocytes, not in human 
hepatocytes. These results demonstrate that momfluorothrin only induced replicative 
Key (K) and Associative (A) 
Event 
Evidence in Rats Evidence in Humans  
Activation of CAR (K) Inferred from CAR-siRNA 
studies and from induction of 
CYP2B enzymes 
 
Probable at high doses  
(Inferred from induction of 
CYP2B mRNA in vitro in 
cultured hepatocytes and in vivo 
in chimeric mice with human 
hepatocytes) 
 
Induction of CYP2B (A) 
[as a marker for CAR 
activation] 
Direct experimental evidence 
in vivo and in vitro in 
cultured hepatocytes  
 
Probable at high doses  
(Experimental evidence in vitro 
in cultured hepatocytes and in 
vivo in chimeric mice with 
human hepatocytes) 
 
Hepatocellular hypertrophy 
(A) 
Direct experimental evidence 
in vivo 
 
Possible at very high doses # 
(Experimental evidence in vivo 
in chimeric mice with human 
hepatocytes treated with NaPB) 
 
Increased hepatocellular 
proliferation (K) 
Direct experimental evidence 
in vivo and in vitro in 
cultured hepatocytes 
 
Not predicted to occur 
(Not observed in cultured 
hepatocytes and in vivo in 
chimeric mice with human 
hepatocytes) 
 
Altered hepatic foci (K) Direct experimental evidence 
in vivo 
 
Not predicted to occur 
Liver tumours Yes Not predicted to occur 
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DNA synthesis in rat and not in human hepatocytes. This conclusion is also strongly 
supported by the chimeric mouse study, where no increase in replicative DNA synthesis 
in human hepatocytes was also observed (Table 10, Fig. 17).  
The data obtained in these studies with the CAR activator momfluorothrin is in 
agreement with literature data on other CAR activators that have shown increased 
replicative DNA synthesis in cultured rodent hepatocytes but not in cultured human 
hepatocytes (Hirose et al., 2009, Lake et al., 2015, Elcombe et al., 2014, Parzefall et al., 
1991, Yamada et al., 2015). As examination of the available data demonstrates that the 
MOA for momfluorothrin-induced rat liver tumor formation is qualitatively not 
plausible for humans, there is no need to consider quantitative differences in either 
kinetic or dynamic factors between rats and humans (Fig. 18). In addition to a 
quantitative difference in response, a quantitative difference in exposure, which is not 
generally the basis for quantitative differences under the WHO/IPCS framework, is also 
discussed here. It should be noted that likely human chronic exposure to 
momfluorothrin would be orders of magnitude lower than momfluorothrin dose levels 
required to produce liver tumors in the rat. Thus, not only is there a qualitative 
difference between the rat and human in the response of the liver cells to the pyrethroid 
CAR activators regarding induction of liver tumors, but also a marked quantitative 
difference in the level of exposure. Thus, based on quantitative considerations, the 
confidence in a lack of effect in humans at expected exposures is even stronger than that 
based only on qualitative considerations. Consequently, momfluorothrin is of no 
carcinogenic hazard or risk for humans. 
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Figure 18. The conclusion of the human risk assessment in the rat liver tumors induced by 
momfluorothrin based on the IPCS framework.  
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Conclusions 
 
The obtained data demonstrated that the MOA for momfluorothrin-induced rat 
hepatocellular tumors was mediated by CAR activation in chapter 1. While some of the 
key (activation of CAR) and associative (CYP2B enzyme induction and hepatocellular 
hypertrophy) events in the MOA for momfluorothrin-induced rat hepatocellular tumor 
formation could occur in human liver, the available in vitro and in vivo experimental 
data demonstrated that human hepatocytes appear to be refractory to the mitogenic 
effects of momfluorothrin in chapter 2. In addition, no stimulation of replicative DNA 
synthesis by NaPB and metofluthrin was demonstrated in vivo in the study utilizing 
chimeric mice with human hepatocytes. Therefore, these data suggested that CAR 
activators including momfluorothrin have no carcinogenic risk for humans.  
Since pyrethroids, including natural pyrethrins, have been used for many years as 
insecticides for household, agricultural, and other applications, the Agency for Toxic 
Substances and Disease Registry (ATSDR) provided an excellent review entitled 
“Toxicological Profile for Pyrethrins and Pyrethroids” (ATSDR, 2003). According to 
this review, no reports were located regarding cancer in humans or animals following 
inhalation or dermal exposure to pyrethrins or natural pyrethroids. However, in the case 
of oral exposure to these chemicals, while pyrethrins and some pyrethroids have been 
shown to cause tumors in rodent models (Tsuji et al., 2012), no reports were located 
regarding cancer in humans. Although there are no epidemiological data for 
momfluorothrin or metofluthrin so far, the conclusion in this study may also be 
supported by epidemiological data for pyrethroids/natural pyrethrins (ATSDR, 2003). 
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